Intravitreal Bevacizumab (Avastin) for Neovascular Age

Ophthalmology
113, 363-372.e5
DOI: 10.1016/j.ophtha.2005.11.019

Citation Report

#	Article	IF	Citations
1	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study. Ophthalmology, 2005, 112, 1035-1047.e9.	5.2	626
2	New Pharmacologic Approaches to Therapy for Age-Related Macular Degeneration. BioDrugs, 2006, 20, 167-179.	4.6	37
3	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opinion on Pharmacotherapy, 2006, 7, 2355-2368.	1.8	8
4	Visual Acuity Change After Intravitreal Triamcinolone in Various Types of Exudative Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 370-376.	1.4	7
5	Promising new treatments for neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs, 2006, 15, 779-793.	4.1	68
6	Ageâ€related macular degenerationâ€"emerging pathogenetic and therapeutic concepts. Annals of Medicine, 2006, 38, 450-471.	3.8	546
7	Evaluating Central Corneal Thickness Measurements With Noncontact Optical Low-Coherence Reflectometry and Contact Ultrasound Pachymetry. American Journal of Ophthalmology, 2006, 142, 164-165.	3.3	15
8	Intravitreal Avastin: The Low Cost Alternative to Lucentis?. American Journal of Ophthalmology, 2006, 142, 141-143.	3.3	117
9	Absence of Histologic Retinal Toxicity of Intravitreal Bevacizumab in a Rabbit Model. American Journal of Ophthalmology, 2006, 142, 162-164.	3.3	103
10	Retinal Pigment Epithelium Tear After Intravitreal Bevacizumab for Exudative Age-related Macular Degeneration. American Journal of Ophthalmology, 2006, 142, 1068-1070.	3.3	62
11	Intravitreal Bevacizumab (AvastinÂ®) in the Treatment of Neovascular Glaucoma. American Journal of Ophthalmology, 2006, 142, 1054-1056.	3.3	242
12	Triple Therapy of Intravitreal Triamcinolone, Photodynamic Therapy, and Pegaptanib Sodium for Choroidal Neovascularization. American Journal of Ophthalmology, 2006, 142, 1072-1074.	3.3	35
13	Retinal Pigment Epithelial Tear After Intravitreal Bevacizumab Injection. American Journal of Ophthalmology, 2006, 142, 1070-1071.e1.	3.3	80
14	Assessment of Retinal Nerve Fiber Layer Using Optical Coherence Tomography and Scanning Laser Polarimetry in Progressive Glaucomatous Optic Neuropathy. American Journal of Ophthalmology, 2006, 142, 1056-1059.	3.3	19
15	Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy. Ophthalmology, 2006, 113, 1695-1705.e6.	5.2	719
16	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 2002-2011.e2.	5.2	187
17	Dose-Ranging Study of Lutein Supplementation in Persons Aged 60 Years or Older. , 2006, 47, 5227.		61
18	Retinal Pigment Epithelial Tear following Intravitreal Injection of Bevacizumab (Avastin). European Journal of Ophthalmology, 2006, 16, 770-773.	1.3	47

#	Article	IF	Citations
19	Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study. , 2006, 47, 4569.		158
20	EVALUATION OF IN VITRO EFFECTS OF BEVACIZUMAB (AVASTIN) ON RETINAL PIGMENT EPITHELIAL, NEUROSENSORY RETINAL, AND MICROVASCULAR ENDOTHELIAL CELLS. Retina, 2006, 26, 512-518.	1.7	107
21	NEOVASCULAR GROWTH FOLLOWING PHOTODYNAMIC THERAPY FOR CHOROIDAL HEMANGIOMA AND NEOVASCULAR REGRESSION AFTER INTRAVITREOUS INJECTION OF TRIAMCINOLONE. Retina, 2006, 26, 693-697.	1.7	13
22	REMOVAL OF SUBMACULAR EXUDATES IN A PATIENT WITH COATS DISEASE: A CASE REPORT. Retina, 2006, 26, 836-839.	1.7	4
23	SILICONE OIL DROPLETS FOLLOWING INTRAVITREAL INJECTION. Retina, 2006, 26, 701-703.	1.7	9
24	REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT. Retina, 2006, 26, 352-354.	1.7	341
25	BIMANUAL VITREOUS SURGERY WITH SLIT-BEAM ILLUMINATION AND A MULTICOATED CONTACT LENS. Retina, 2006, 26, 708-709.	1.7	1
26	CHOROIDAL NEOVASCULAR MEMBRANE ASSOCIATED WITH MELANOCYTOMA OF THE OPTIC NERVE. Retina, 2006, 26, 703-704.	1.7	1
27	CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUM: OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHY FEATURES. Retina, 2006, 26, 704-706.	1.7	4
28	NEOVASCULAR GROWTH FOLLOWING PHOTODYNAMIC THERAPY FOR CHOROIDAL HEMANGIOMA AND NEOVASCULAR REGRESSION AFTER INTRAVITREOUS INJECTION OF TRIAMCINOLONE. Retina, 2006, 26, 693-697.	1.7	14
29	Ranibizumab Treatment of Patients With Ocular Diseases. International Ophthalmology Clinics, 2006, 46, 131-140.	0.7	13
30	ABNORMAL RESPONSE OF THE RETINAL PIGMENT EPITHELIUM TO PHOTODYNAMIC THERAPY IN A CHILD. Retina, 2006, 26, 834-836.	1.7	5
31	CRYSTALLINE RETINOPATHY FROM NASAL INGESTION OF METHAMPHETAMINE. Retina, 2006, 26, 823-824.	1.7	20
32	SILICONE OIL DROPLETS FOLLOWING INTRAVITREAL INJECTION. Retina, 2006, 26, 701-703.	1.7	61
33	EVALUATION OF ANTERIOR CHAMBER INFLAMMATORY ACTIVITY IN EYES TREATED WITH INTRAVITREAL BEVACIZUMAB. Retina, 2006, 26, 877-881.	1.7	58
34	USE OF INTRAVITREAL BEVACIZUMAB AS A PREOPERATIVE ADJUNCT FOR TRACTIONAL RETINAL DETACHMENT REPAIR IN SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2006, 26, 699-700.	1.7	176
35	TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA WITH INTRAVITREAL BEVACIZUMAB. Retina, 2006, 26, 960-963.	1.7	82
36	ENDOPHTHALMITIS AFTER 25-GAUGE TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY. Retina, 2006, 26, 830-831.	1.7	66

#	Article	IF	Citations
37	INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE) Tj ETQq0 0 0 rgBT /Overloc	1.7	237
38	Expanding Treatment Options in Age-related Macular Degeneration. International Ophthalmology Clinics, 2006, 46, 123-129.	0.7	9
39	EASY AND EFFECTIVE WAY TO REMOVE RESIDUAL SILICONE OIL DROPLETS IN PHAKIC PATIENTS. Retina, 2006, 26, 697-699.	1.7	1
40	SIX-MONTH STABILITY OF BEVACIZUMAB (AVASTIN) BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER WITHDRAWAL INTO A SYRINGE AND REFRIGERATION OR FREEZING. Retina, 2006, 26, 519-522.	1.7	96
41	DELAYED EXTRUSION OF GANCICLOVIR IMPLANT. Retina, 2006, 26, 829-830.	1.7	3
42	VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2006, 26, 994-998.	1.7	110
43	Avastin and New Treatments for AMD: Where Are We?. Retina, 2006, 26, 853-858.	1.7	32
44	CORNEAL GRAFT DEHISCENCE DURING PNEUMATIC RETINOPEXY. Retina, 2006, 26, 707.	1.7	2
45	SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2006, 26, 495-511.	1.7	484
46	REGRESSION OF NEOVASCULAR IRIS VESSELS BY INTRAVITREAL INJECTION OF BEVACIZUMAB. Retina, 2006, 26, 839-841.	1.7	96
47	CASE OF ANTERIOR UVEITIS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB. Retina, 2006, 26, 841-842.	1.7	52
48	BIMANUAL VITREOUS SURGERY WITH SLIT-BEAM ILLUMINATION AND A MULTICOATED CONTACT LENS. Retina, 2006, 26, 708-709.	1.7	3
49	CHOROIDAL NEOVASCULAR MEMBRANE ASSOCIATED WITH MELANOCYTOMA OF THE OPTIC NERVE. Retina, 2006, 26, 703-704.	1.7	5
50	CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUM: OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHY FEATURES. Retina, 2006, 26, 704-706.	1.7	22
51	TOTAL EXUDATIVE RETINAL DETACHMENT IN COATS DISEASE: BIOCHEMICAL ANALYSIS OF THE SUBRETINAL EXUDATE. Retina, 2006, 26, 831-833.	1.7	1
52	MYCOBACTERIUM ABSCESSUS ENDOPHTHALMITIS: TREATMENT DILEMMA AND REVIEW OF THE LITERATURE. Retina, 2006, 26, 826-829.	1.7	19
53	MODIFIED LASER-INDUCED CHORIORETINAL ANASTOMOSIS FOR TREATMENT OF LONGSTANDING PERFUSED CENTRAL RETINAL VEIN OCCLUSION. Retina, 2006, 26, 824-825.	1.7	4
54	COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIN AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2006, 26, 988-993.	1.7	112

#	Article	IF	Citations
55	INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA. Retina, 2006, 26, 999-1005.	1.7	423
56	Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Acta Ophthalmologica, 2006, 84, 713-714.	0.3	21
57	Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmologica, 2006, 84, 831-833.	0.3	14
58	Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmologica, 2006, 84, 833-834.	0.3	32
59	Intravitreal bevacizumab for peripapillary classic subretinal neovascularization. Acta Ophthalmologica, 2006, 85, 340-341.	0.3	9
60	Macular degeneration: recent advances and therapeutic opportunities. Nature Reviews Neuroscience, 2006, 7, 860-872.	10.2	199
61	Bevacizumab: a new way of doing business?. Eye, 2006, 20, 985-987.	2.1	4
62	Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 245, 68-73.	1.9	112
67	Maculoplasty for age-related macular degeneration: Reengineering Bruch's membrane and the human macula. Progress in Retinal and Eye Research, 2006, 25, 539-562.	15.5	47
68	Non-viral gene therapy for diabetic retinopathy. Drug Development Research, 2006, 67, 835-841.	2.9	8
69	A Very Effective Treatment for Neovascular Macular Degeneration. New England Journal of Medicine, 2006, 355, 1493-1495.	27.0	66
70	Evolving European guidance on the medical management of neovascular age related macular degeneration. British Journal of Ophthalmology, 2006, 90, 1188-1196.	3.9	62
71	Vascular endothelial growth factor biology: clinical implications for ocular treatments. British Journal of Ophthalmology, 2006, 90, 1542-1547.	3.9	149
72	The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. British Journal of Ophthalmology, 2006, 90, 1344-1349.	3.9	502
73	Some ethical considerations for the "off-label" use of drugs such as Avastin. British Journal of Ophthalmology, 2006, 90, 1218-1219.	3.9	13
74	New treatments for age-related macular degeneration. Age and Ageing, 2006, 36, 8-10.	1.6	5
75	DEVELOPMENT OF RANIBIZUMAB, AN ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2006, 26, 859-870.	1.7	753
76	Emerging drugs for age-related macular degeneration. Expert Opinion on Emerging Drugs, 2006, 11, 725-740.	2.4	16

#	Article	IF	Citations
77	Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. British Journal of Ophthalmology, 2006, 90, 1316-1321.	3.9	109
78	Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 2006, 6, 1237-1245.	3.1	32
79	Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. British Journal of Ophthalmology, 2006, 90, 982-986.	3.9	32
80	Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. British Journal of Ophthalmology, 2007, 91, 1716-1717.	3.9	23
81	VEGF inhibition: latest developments. Expert Review of Ophthalmology, 2007, 2, 621-632.	0.6	0
82	Bevacizumab for ophthalmic diseases. Expert Review of Ophthalmology, 2007, 2, 369-378.	0.6	4
83	PtdIns-4,5-P2as a potential therapeutic target for pathologic angiogenesis. Expert Opinion on Therapeutic Targets, 2007, 11, 443-451.	3.4	5
84	Intravitreal Bevacizumab Combined with Cataract Surgery for Treatment of Exudative Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 599-600.	1.4	19
85	Short-Term Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Obstruction and Diabetic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 387-394.	1.4	17
86	Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. British Journal of Ophthalmology, 2007, 91, 785-789.	3.9	30
87	Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. British Journal of Ophthalmology, 2007, 91, 157-160.	3.9	137
88	Diffusion of Macromolecule Through Retina After Experimental Branch Retinal Vein Occlusion and Estimate of Intraretinal Barrier. Current Drug Metabolism, 2007, 8, 151-156.	1.2	22
89	Current Treatment of Age-Related Macular Degeneration. Optometry and Vision Science, 2007, 84, E559-E572.	1.2	29
90	Ophthalmology human resource projections: are we heading for a crisis in the next 15 years?. Canadian Journal of Ophthalmology, 2007, 42, 34-38.	0.7	36
91	CLINICAL AND FUNDAMENTAL ASPECTS OF ANGIOGENESIS AND ANTI-ANGIOGENESIS. Acta Clinica Belgica, 2007, 62, 162-169.	1.2	16
92	Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Exudative Age-Related Macular Degeneration and Diffuse Diabetic Macular Edema. Ophthalmic Research, 2007, 39, 139-142.	1.9	47
94	A view on new drugs for macular degeneration. Drug and Therapeutics Bulletin, 2007, 45, 49-52.	0.3	1
95	Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration. Annual Review of Medicine, 2007, 58, 491-504.	12.2	227

#	Article	IF	Citations
96	Infectious and Noninfectious Endophthalmitis After Intravitreal Bevacizumab. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 240-242.	1.4	68
97	Anti-VEGF agents in the treatment of neovascular AMD. Expert Review of Ophthalmology, 2007, 2, 459-465.	0.6	1
98	Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. British Journal of Ophthalmology, 2007, 91, 827-831.	3.9	48
99	Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. British Journal of Ophthalmology, 2007, 91, 1244-1246.	3.9	132
100	RANIBIZUMAB (LUCENTIS) VS. BEVACIZUMAB (AVASTIN): THE DEBATE RAGES ON. Evidence-Based Ophthalmology, 2007, 8, 196-198.	0.0	0
101	Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. British Journal of Ophthalmology, 2007, 91, 161-165.	3.9	135
102	The Therapeutic Effects of Intravitreal Bevacizumab in a Patient with Recalcitrant Idiopathic Polypoidal Choroidal Vasculopathy. Seminars in Ophthalmology, 2007, 22, 127-131.	1.6	28
103	Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). British Journal of Ophthalmology, 2007, 91, 804-807.	3.9	200
104	Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes. Investigative Ophthalmology and Visual Science, 2007, 48, 1773-1781.	3.3	117
105	Aptamers in the virologists' toolkit. Journal of General Virology, 2007, 88, 351-364.	2.9	71
106	Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. JAMA Ophthalmology, 2007, 125, 1363.	2.4	80
107	ROLE OF GENETIC FACTORS AND INFLAMMATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 269-275.	1.7	53
108	INFLUENCE OF VERTEPORFIN PHOTODYNAMIC THERAPY ON INFLAMMATION IN HUMAN CHOROIDAL NEOVASCULAR MEMBRANES SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 713-723.	1.7	32
109	STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 701-706.	1.7	39
110	PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMAB. Retina, 2007, 27, 1196-1200.	1.7	64
111	INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION AS PRIMARY TREATMENT OF INFLAMMATORY CHOROIDAL NEOVASCULARIZATION. Retina, 2007, 27, 1180-1186.	1.7	72
112	TEARS OF THE RETINAL PIGMENT EPITHELIUM. Retina, 2007, 27, 523-534.	1.7	156
113	RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 541-551.	1.7	160

#	Article	IF	Citations
114	TREATMENT OF NAÃVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB. Retina, 2007, 27, 851-856.	1.7	23
115	MULTIFOCAL ELECTRORETINOGRAPHY IN PATIENTS WITH EXUDATIVE AMD AND INTRAVITREAL TREATMENT WITH PEGAPTANIB SODIUM. Retina, 2007, 27, 864-872.	1.7	11
116	INTRAVITREAL BEVACIZUMAB FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 445-450.	1.7	59
117	Drug delivery methods for posterior segment disease. Current Opinion in Ophthalmology, 2007, 18, 235-239.	2.9	85
118	REBOUND MACULAR EDEMA FOLLOWING BEVACIZUMAB (AVASTIN) THERAPY FOR RETINAL VENOUS OCCLUSIVE DISEASE. Retina, 2007, 27, 426-431.	1.7	121
119	INTRAVITREAL BEVACIZUMAB (AVASTIN) IN CENTRAL RETINAL VEIN OCCLUSION. Retina, 2007, 27, 1013-1019.	1.7	64
120	INTRAVITREAL BEVACIZUMAB COMBINED WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF OCCULT CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH SEROUS PIGMENT EPITHELIUM DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 891-896.	1.7	36
121	RANIBIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 846-850.	1.7	28
122	Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration. Retina, 2007, 27, 1163-1165.	1.7	15
123	Safety Profile of Bevacizumab on Cultured Human Corneal Cells. Cornea, 2007, 26, 977-982.	1.7	94
124	Antiangiogenic Therapy in Neovascular Age-related Macular Degeneration. International Ophthalmology Clinics, 2007, 47, 117-137.	0.7	12
125	INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. Retina, 2007, 27, 419-425.	1.7	234
126	INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 439-444.	1.7	154
127	INTRAVITREAL BEVACIZUMAB (AVASTIN) IN A PEDIATRIC CASE OF PATHOLOGIC MYOPIA. Retinal Cases and Brief Reports, 2007, 1, 192-194.	0.6	4
129	Intravitreal Bevacizumab (Avastin) for the Treatment of Chorioretinal Vascular Diseases. Techniques in Ophthalmology, 2007, 5, 40-45.	0.1	0
130	Ranibizumab in the treatment of age-related macular degeneration. Aging Health, 2007, 3, 9-14.	0.3	0
131	OPTICAL COHERENCE TOMOGRAPHY FINDINGS DURING PEGAPTANIB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 724-729.	1.7	7
132	Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration. Yearbook of Ophthalmology, 2007, 2007, 141-142.	0.0	0

#	Article	IF	Citations
133	INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 432-438.	1.7	64
134	INTRAVITREAL BEVACIZUMAB FOR THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION IN PSEUDOXANTHOMA ELASTICUM. Retina, 2007, 27, 897-902.	1.7	82
135	RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 535-540.	1.7	62
136	Intravitreal Bevacizumab for Subfoveal Idiopathic Choroidal Neovascularization. JAMA Ophthalmology, 2007, 125, 1487.	2.4	51
137	Ocular Neovascularization: Basic Mechanisms and Therapeutic Advances. Survey of Ophthalmology, 2007, 52, S3-S19.	4.0	118
138	Intravitreal Bevacizumab. Ophthalmology, 2007, 114, 400.	5.2	1
140	Intravitreal Bevacizumab for Treatment of Uveitic Macular Edema. Ophthalmology, 2007, 114, 1574-1579.e1.	5.2	137
141	Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Ophthalmology, 2007, 114, 743-750.	5.2	318
142	Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration. Ophthalmology, 2007, 114, 1179-1185.	5.2	134
143	Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. Ophthalmology, 2007, 114, 2190-2196.e2.	5.2	127
144	Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia. Ophthalmology, 2007, 114, 1736-1742.	5.2	99
145	Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab. Ophthalmology, 2007, 114, 2168-2173.	5.2	195
146	Progressive Visual Loss in Subfoveal Exudation in Age-related Macular Degeneration: A Meta-analysis Using Lineweaver-Burke Plots. American Journal of Ophthalmology, 2007, 143, 83-89.e2.	3.3	44
147	Intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Short-term Study. American Journal of Ophthalmology, 2007, 143, 510-512.	3.3	86
148	Retinal Pigment Epithelial Tear after Intravitreal Ranibizumab. American Journal of Ophthalmology, 2007, 143, 505-507.	3.3	73
149	Changes in Select Redox Proteins of the Retinal Pigment Epithelium in Age-related Macular Degeneration. American Journal of Ophthalmology, 2007, 143, 607-615.e2.	3.3	143
150	Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin. American Journal of Ophthalmology, 2007, 143, 977-983.e1.	3.3	159
151	Ultrastructural Findings in the Primate Eye After Intravitreal Injection of Bevacizumab. American Journal of Ophthalmology, 2007, 143, 995-1002.e2.	3.3	216

#	Article	IF	Citations
152	Optical Coherence Tomography Reader Agreement in Neovascular Age-related Macular Degeneration. American Journal of Ophthalmology, 2007, 144, 37-44.e1.	3.3	35
153	Treatment of Exudative Age-related Macular Degeneration: Many Factors to Consider. American Journal of Ophthalmology, 2007, 144, 281-283.	3.3	14
154	Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients. American Journal of Ophthalmology, 2007, 144, 627-637.e2.	3.3	210
155	Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye. Experimental Eye Research, 2007, 84, 922-933.	2.6	9
156	Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery, 2007, 33, 2098-2105.	1.5	51
157	A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Medical Hypotheses, 2007, 68, 799-801.	1.5	37
158	VEGF-A and the Induction of Pathological Angiogenesis. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 251-275.	22.4	342
159	A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genetics in Medicine, 2007, 9, 413-426.	2.4	134
160	Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Current Medical Research and Opinion, 2007, 23, 477-487.	1.9	52
161	Combination Therapy for Choroidal Neovascularisation. Drugs and Aging, 2007, 24, 979-990.	2.7	18
162	Targeting Vascular Endothelial Growth Factor. Drugs and Aging, 2007, 24, 643-662.	2.7	43
163	21st Century treatment of diabetic retinopathy. Expert Review of Endocrinology and Metabolism, 2007, 2, 623-631.	2.4	3
164	Bevacizumab for Neovascular Ocular Diseases. Annals of Pharmacotherapy, 2007, 41, 614-625.	1.9	156
165	A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis. Expert Opinion on Therapeutic Patents, 2007, 17, 1351-1363.	5.0	3
166	Local Tolerance and Systemic Safety of Pegaptanib Sodium in the Dog and Rabbit. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 452-466.	1.4	37
167	Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. BioDrugs, 2007, 21, 245-257.	4.6	63
168	The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications. American Journal of Cardiovascular Drugs, 2007, 7, 393-398.	2.2	30
169	Macular Degeneration. Annual Review of Medicine, 2007, 58, 477-490.	12.2	26

#	Article	IF	Citations
170	Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey. , 2007, 48, 2814.		254
171	Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opinion on Investigational Drugs, 2007, 16, 1525-1540.	4.1	31
172	Pegaptanib sodium for the treatment of ocular vascular disease. Expert Review of Ophthalmology, 2007, 2, 45-60.	0.6	1
173	Regression of radiation-induced macular edema after systemic bevacizumab. Canadian Journal of Ophthalmology, 2007, 42, 748-749.	0.7	19
174	Bevacizumab in glaucoma: a review. Canadian Journal of Ophthalmology, 2007, 42, 812-815.	0.7	18
175	Ocular Photodynamic Therapy â€“ Standard Applications and New Indications (Part 2). Ophthalmologica, 2007, 221, 282-291.	1.9	25
176	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evidence, 2007, .	4.7	5
177	Photodynamic Therapy on Age-related Macular Degeneration.. Nippon Laser Igakkaishi, 2007, 28, 176-181.	0.0	0
178	The effects of the subconjunctival injection of bevacizumab (AvastinÂ®) on angiogenesis in the rat cornea. Anais Da Academia Brasileira De Ciencias, 2007, 79, 389-394.	0.8	58
179	Intravitreal Bevacizumab for Neovascular Glaucoma following Central Retinal Artery Occlusion. European Journal of Ophthalmology, 2007, 17, 269-271.	1.3	44
181	Trials That Matter: Two Faces of Progress in the Treatment of Age-Related Macular Degeneration. Annals of Internal Medicine, 2007, 146, 532.	3.9	9
182	Retinal Detachment with Macular Hole Following Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection. Korean Journal of Ophthalmology: KJO, 2007, 21, 185.	1.1	24
183	Error Correction and Quantitative Subanalysis of Optical Coherence Tomography Data Using Computer-Assisted Grading. , 2007, 48, 839.		114
184	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. British Journal of Ophthalmology, 2007, 91, 128-130.	3.9	17
185	Intravitreal Bevacizumab (Avastin) as Primary Treatment for Myopic Choroidal Neovascularization. European Journal of Ophthalmology, 2007, 17, 620-626.	1.3	42
186	Intravitreal Bevacizumab Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 6-Month Results of an Open-Label Uncontrolled Clinical Study. European Journal of Ophthalmology, 2007, 17, 230-237.	1.3	32
187	Managing neovascular ageâ€related macular degeneration: a step into the light. Medical Journal of Australia, 2007, 186, 276-277.	1.7	1
188	Molecular targets for retinal vascular diseases. Journal of Cellular Physiology, 2007, 210, 575-581.	4.1	42

#	Article	IF	Citations
189	Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmology, 2007, 7, 10.	1.4	38
190	Functional loss in early age-related maculopathy: the ischaemia postreceptoral hypothesis. Eye, 2007, 21, 689-696.	2.1	47
191	Screening for wet AMD by optometrists: resistance to change or professional rivalry?. Eye, 2007, 21, 272-273.	2.1	1
192	Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye, 2007, 21, 408-409.	2.1	46
193	Retinal pigment epithelial tear following intravitreal bevacizumab. Eye, 2007, 21, 424-425.	2.1	15
194	Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra). Eye, 2007, 21, 1540-1541.	2.1	10
195	Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye, 2007, 21, 1541-1541.	2.1	56
196	Clinical applications and new developments of optical coherence tomography: an evidenceâ€based review. Australasian journal of optometry, The, 2007, 90, 317-335.	1.3	73
197	New treatments for neovascular age-related macular degeneration: when should we use them?. Acta Ophthalmologica, 2007, 85, 5-5.	0.3	0
198	Intravitreal VEGF-inhibitors: is AvastinÂ® a generic substitute for LucentisÂ®?. Acta Ophthalmologica, 2007, 85, 2-4.	0.3	17
199	Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmologica, 2007, 85, 563-565.	0.3	12
200	Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmologica, 2007, 85, 526-533.	0.3	20
201	Reading performance with lowâ€vision aids and visionâ€related quality of life after macular translocation surgery in patients with ageâ€related macular degeneration. Acta Ophthalmologica, 2007, 85, 877-882.	0.3	11
202	Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmologica, 2007, 85, 486-494.	0.3	45
203	Ranibizumab for the treatment of neovascular AMD. International Journal of Clinical Practice, 2007, 61, 501-509.	1.7	21
204	Surgical treatment of age-related macular degeneration: will there be a role in the future?. Clinical and Experimental Ophthalmology, 2007, 35, 070130044246010-???.	2.6	1
205	Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clinical and Experimental Ophthalmology, 2007, 35, 745-748.	2.6	71
206	Recent developments in optical coherence tomography for imaging the retina. Progress in Retinal and Eye Research, 2007, 26, 57-77.	15.5	304

#	Article	IF	Citations
207	Management of neovascular age-related macular degeneration. Progress in Retinal and Eye Research, 2007, 26, 437-451.	15.5	79
208	Large subretinal hemorrhage after intravitreal bevacizumab (AvastinÂ®) for age-related macular degeneration. Annals of Ophthalmology, 2007, 39, 51-52.	0.0	11
209	Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. International Ophthalmology, 2007, 26, 191-193.	1.4	21
212	Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 215-220.	1.9	34
213	Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 245, 941-948.	1.9	84
214	Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1085-1095.	1.9	31
215	Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1273-1280.	1.9	57
216	Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1825-1829.	1.9	42
217	Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1837-1842.	1.9	79
218	Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1731-1733.	1.9	48
219	Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 246, 17-25.	1.9	35
220	Twelve-month safety of intravitreal injections of bevacizumab (AvastinÂ®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 246, 81-87.	1.9	401
221	Progress in defining the molecular biology of age related macular degeneration. Human Genetics, 2007, 122, 219-236.	3.8	64
222	Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. International Ophthalmology, 2008, 28, 311-316.	1.4	36
227	Intravitreal anti-VEGF therapy in neovascular age-related macular degeneration: Bevacizumab versus Ranibizumab. Spektrum Der Augenheilkunde, 2008, 22, 370-375.	0.3	1
229	Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Japanese Journal of Ophthalmology, 2008, 52, 52-56.	1.9	21
230	Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 811-815.	1.9	20
231	Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 837-842.	1.9	162

#	Article	IF	Citations
232	A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports). Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1235-1239.	1.9	82
233	A randomised, double-masked phase III/IV study of the efficacy and safety of AvastinÂ® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials, 2008, 9, 56.	1.6	31
234	Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib^{Â®} treatment. Acta Ophthalmologica, 2008, 86, 456-458.	1.1	33
235	Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmologica, 2008, 86, 365-371.	1.1	62
236	Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmologica, 2008, 86, 372-376.	1.1	179
237	A prospective study on intravitreal bevacizumab (Avastin^{Â®}) for neovascular ageâ€related macular degeneration of different durations. Acta Ophthalmologica, 2008, 86, 482-489.	1.1	86
238	The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye, 2008, 22, 761-767.	2.1	40
239	Anti-VEGF therapy: comparison of current and future agents. Eye, 2008, 22, 1330-1336.	2.1	92
240	Lack of benefit of early awareness to age-related macular degeneration. Eye, 2008, 22, 777-781.	2.1	13
241	Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection. Eye, 2008, 22, 799-807.	2.1	51
242	Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye, 2008, 22, 82-86.	2.1	67
243	Progress in understanding and treating age-related macular degeneration. Eye, 2008, 22, 739-741.	2.1	4
244	Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye, 2008, 22, 1168-1171.	2.1	32
245	Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular ageâ€related macular degeneration: a review of current practice. Australasian journal of optometry, The, 2008, 91, 427-437.	1.3	60
246	Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative ageâ€related macular degeneration. Clinical and Experimental Ophthalmology, 2008, 36, 252-256.	2.6	55
247	Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clinical and Experimental Ophthalmology, 2008, 36, 449-454.	2.6	31
248	Intravitreal bevacizumab (Avastin) for neovascular ageâ€related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clinical and Experimental Ophthalmology, 2008, 36, 748-755.	2.6	27
249	Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPEâ€induced sprouting angiogenesis in vitro. FEBS Letters, 2008, 582, 3097-3102.	2.8	61

#	Article	IF	Citations
251	Introduction: Uveal melanoma. Acta Ophthalmologica, 2008, 86, 7-19.	1.1	0
252	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. , 2008, , CD005139.		60
253	Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration. Mayo Clinic Proceedings, 2008, 83, 231-234.	3.0	12
254	Molecular Biomethods Handbook. Springer Protocols, 2008, , .	0.3	13
255	Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. NeuroToxicology, 2008, 29, 1131-1135.	3.0	32
256	Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery, 2008, 34, 70-75.	1.5	95
257	Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model. American Journal of Ophthalmology, 2008, 145, 424-431.e1.	3.3	107
258	Treatment of Neovascular Age-related Macular Degeneration with Intravitreal Bevacizumab: Efficacy of Three Consecutive Monthly Injections. American Journal of Ophthalmology, 2008, 146, 91-95.	3.3	37
259	Randomized Multicenter Trial of More Intense and Standard Early Verteporfin Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 134-140.	5.2	10
260	Quantitative Comparison of Optical Coherence Tomography after Pegaptanib or Bevacizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 347-354.e2.	5.2	40
261	Retinal Precursors and the Development of Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 1026-1031.	5.2	191
262	Intraocular Concentration of Triamcinolone Acetonide after Intravitreal Injection in the Rabbit Eye. Ophthalmology, 2008, 115, 1372-1375.	5.2	30
263	Acute Intraocular Inflammation after Intravitreous Injections of Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. Ophthalmology, 2008, 115, 1911-1915.e1.	5.2	108
264	Antiâ€“Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 1837-1846.	5.2	132
265	Relationship Between Optical Coherence Tomography Retinal Parameters and Visual Acuity in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 2206-2214.	5.2	94
266	Connexin 43 contributes to differentiation of retinal pigment epithelial cells via cyclic AMP signaling. Biochemical and Biophysical Research Communications, 2008, 366, 532-538.	2.1	30
267	Comparison of Multiple Reduced-dose and Standard Light Application in Photodynamic Therapy in an Animal Model of Choroidal Neovascularization. Journal of the Chinese Medical Association, 2008, 71, 135-142.	1.4	4
268	Shall we use Avastin^{Â®} or Lucentis^{Â®} for ocular neovascularization?. Acta Ophthalmologica, 2008, 86, 352-355.	1.1	6

#	Article	IF	Citations
271	Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Canadian Journal of Ophthalmology, 2008, 43, 576-580.	0.7	17
272	Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. British Journal of Ophthalmology, 2008, 92, 1450-1455.	3.9	147
273	Toxicity and Intraocular Properties of a Novel Long-Acting Anti-Proliferative and Anti-Angiogenic Compound IMS2186. Current Eye Research, 2008, 33, 599-609.	1.5	17
274	Subconjunctival Bevacizumab Injection for Corneal Neovascularization in Recurrent Pterygium. Current Eye Research, 2008, 33, 23-28.	1.5	112
275	Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. British Journal of Ophthalmology, 2008, 92, 213-216.	3.9	364
276	Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology, 2008, 92, 356-360.	3.9	68
278	Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2008, 92, 70-73.	3.9	232
279	Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 1248-1252.	3.9	14
280	Interaction between Bevacizumab and Murine VEGF-A: A Reassessment. , 2008, 49, 522.		149
281	Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. Annual Review of Pharmacology and Toxicology, 2008, 48, 61-78.	9.4	34
282	Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. British Journal of Ophthalmology, 2008, 92, 1424-1428.	3.9	17
283	Bevacizumab Treatment for Subfoveal Choroidal Neovascularization From Causes Other Than Age-Related Macular Degeneration. JAMA Ophthalmology, 2008, 126, 941.	2.4	73
284	Automatic segmentation in three-dimensional analysis of fibrovascular pigmentepithelial detachment using high-definition optical coherence tomography. British Journal of Ophthalmology, 2008, 92, 197-203.	3.9	71
285	PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î±</mml:mi></mml:math>Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration. PPAR Research, 2008, 2008, 1-5.	2.4	16
286	Ranibizumab for neovascular age-related macular degeneration. American Journal of Health-System Pharmacy, 2008, 65, 1805-1814.	1.0	25
287	Optical coherence tomography: limits of the retinal-mapping program in age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 933-935.	3.9	27
288	Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration. , 2008, 49, 3115.		126
289	Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture. , 2008, 49, 3164.		38

#	Article	IF	Citations
290	A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 1636-1641.	3.9	54
294	The Treatment of Choroidal Neovascularisations with Intravitreal Injections of Bevacizumab (AvastinÂ®). Klinische Monatsblatter Fur Augenheilkunde, 2008, 225, 380-384.	0.5	6
296	Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 210-212.	3.9	26
297	Intravitreal Bevacizumab and Triamcinolone Acetonide Combination Therapy for Exudative Neovascular Age-Related Macular Degeneration: Short-Term Optical Coherence Tomography Results. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 15-24.	1.4	16
300	Early Effects of Triamcinolone on Vascular Endothelial Growth Factor and Endostatin in Human Choroidal Neovascularization. JAMA Ophthalmology, 2008, 126, 193.	2.4	11
301	Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration. Mayo Clinic Proceedings, 2008, 83, 231-234.	3.0	30
302	COMPARISON OF 2.5 mg/kg AND 5 mg/kg SYSTEMIC BEVACIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 1375-1386.	1.7	10
303	Combined Use of Superficial Keratectomy and Subconjunctival Bevacizumab Injection for Corneal Neovascularization. Cornea, 2008, 27, 1090-1092.	1.7	30
304	Intravitreal Bevacizumab in the Management of Choroidal Neovascular Membrane Secondary to Choroidal Osteoma. European Journal of Ophthalmology, 2008, 18, 466-468.	1.3	22
305	Intracameral Avastin Dramatically Resolves Iris Neovascularization and Reverses Neovascular Glaucoma. European Journal of Ophthalmology, 2008, 18, 255-262.	1.3	68
306	INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2008, 28, 689-695.	1.7	43
307	LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA. Retina, 2008, 28, 1053-1060.	1.7	152
308	INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION. Retina, 2008, 28, 564-567.	1.7	145
309	SURVEILLANCE FOR POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE USE OF INTRAVITREAL BEVACIZUMAB FOR RETINAL AND CHOROIDAL VASCULAR DISEASE. Retina, 2008, 28, 1151-1158.	1.7	69
310	BEVACIZUMAB (AVASTIN) DOES NOT HARM RETINAL FUNCTION AFTER INTRAVITREAL INJECTION AS SHOWN BY ELECTRORETINOGRAPHY IN ADULT MICE. Retina, 2008, 28, 46-55.	1.7	40
311	CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA. Retina, 2008, 28, 1308-1313.	1.7	77
312	Subconjunctival Bevacizumab for Corneal Neovascularization. Cornea, 2008, 27, 992-995.	1.7	74
313	The cost of vision for vitreoretinal interventions. Current Opinion in Ophthalmology, 2008, 19, 195-201.	2.9	2

#	Article	IF	Citations
314	OUTCOME OF BEVACIZUMAB (AVASTIN) INJECTION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION AND LOW VISUAL ACUITY. Retina, 2008, 28, 1302-1307.	1.7	25
315	INTRAVITREAL BEVACIZUMAB TREATMENT OF RETINAL TELANGIECTASIS COMPLICATED BY SUBRETINAL NEOVASCULARIZATION. Retinal Cases and Brief Reports, 2008, 2, 141-144.	0.6	1
316	INTRAVITREAL BEVACIZUMAB (AVASTIN) PREVENTION OF PANRETINAL PHOTOCOAGULATION-INDUCED COMPLICATIONS IN PATIENTS WITH SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2008, 28, 1319-1324.	1.7	45
317	Surgical management of retinopathy of prematurity. Current Opinion in Ophthalmology, 2008, 19, 384-390.	2.9	24
318	INTRAVITREAL INJECTION OF BEVACIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 675-681.	1.7	44
319	Treatment of Radiation Maculopathy With Intravitreal Injection of Bevacizumab (Avastin). Retina, 2008, 28, 964-968.	1.7	81
320	LACQUER CRACK FORMATION AND CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA. Retina, 2008, 28, 1124-1131.	1.7	97
321	Effects of Macular Ischemia on the Outcome of Intravitreal Bevacizumab Therapy for Diabetic Macular Edema. Retina, 2008, 28, 957-963.	1.7	108
322	PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 1387-1394.	1.7	56
323	Subconjunctival Bevacizumab Injection for Corneal Neovascularization. Cornea, 2008, 27, 142-147.	1.7	127
324	Bevacizumab (Avastin) and Argon Laser to Treat Neovascularization in Corneal Transplant Surgery. Cornea, 2008, 27, 1195-1199.	1.7	61
325	Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone. Clinical Ophthalmology, 2008, 2, 71.	1.8	2
326	Update on the Treatment of Diabetic Retinopathy. Scientific World Journal, The, 2008, 8, 98-120.	2.1	32
327	Angioid streaks, clinical course, complications, and current therapeutic management. Therapeutics and Clinical Risk Management, 0, , 81.	2.0	7
328	Treatment of age-related macular degeneration: focus on ranibizumab. Clinical Ophthalmology, 2008, 2, 1.	1.8	40
329	Autologous Transplantation of RPE with Partial-Thickness Choroid after Mechanical Debridement of Bruch Membrane in the Rabbit. , 2008, 49, 3185.		15
330	Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. Journal of Clinical Investigation, 2008, 118, 2337-46.	8.2	92
331	Subretinal Bevacizumab Detection after Intravitreous Injection in Rabbits. , 2008, 49, 1097.		40

#	Article	IF	Citations
332	Current and emerging therapies for the treatment of age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 377.	1.8	46
333	Long-term Effect of Intravitreal Bevacizumab for CNV Secondary to Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2008, 49, 1935.	0.2	9
334	Single-Session Photodynamic Therapy Combined with Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2008, 18, 297-300.	1.3	19
335	Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 727.	1.8	9
336	Intravitreal Bevacizumab versus Combined Bevacizumab-Triamcinolone versus Macular Laser Photocoagulation in Diabetic Macular Edema. European Journal of Ophthalmology, 2008, 18, 941-948.	1.3	91
337	The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy. Korean Journal of Ophthalmology: KJO, 2008, 22, 92.	1.1	63
338	AntiangiogÃªnicos no glaucoma. Revista Brasileira De Oftalmologia, 2008, 67, 313-320.	0.1	0
339	Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and Diabetic Macular Edema. Journal of Korean Ophthalmological Society, 2008, 49, 1275.	0.2	6
340	Intravitreal Bevacizumab Injection as Preoperative Adjuvant of Vitrectomy for Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 731.	0.2	1
341	Age-related macular degeneration: current treatments. Clinical Ophthalmology, 2009, 3, 155.	1.8	43
342	Short-Term Effect of Intravitreal Bevacizumab Injection for Choroidal Neovascularization Associated With Degenerative Myopia. Journal of Korean Ophthalmological Society, 2009, 50, 1334.	0.2	0
343	Effect of Bevacizumab on Survival and Production of Nitric Oxide in Trabecular Meshwork Cells. Journal of Korean Ophthalmological Society, 2009, 50, 1404.	0.2	5
344	Effects and Prognostic Factors of Intravitreal Bevacizumab Injection on Choroidal Neovascularization from Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2009, 50, 202.	0.2	7
345	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?. Clinical Interventions in Aging, 2009, 4, 457.	2.9	21
346	The Efficacy of Intravitreal Bevacizumab in the Treatment of Macular Edema. Journal of Korean Ophthalmological Society, 2009, 50, 1232.	0.2	0
347	Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin®) for AMD followed by controlateral sympathetic ophthalmia. Clinical Ophthalmology, 2009, 3, 457.	1.8	35
348	Testing intravitreal toxicity of rapamycin in rabbit eyes. Arquivos Brasileiros De Oftalmologia, 2009, 72, 18-22.	0.5	18
349	Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clinical Ophthalmology, 0, , 709.	1.8	15

#	Article	IF	Citations
350	Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments. Clinical Medicine Therapeutics, 2009, 1, CMT.S2225.	0.1	0
351	Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema. Journal of Ophthalmology, 2009, 2009, 1-6.	1.3	6
352	Serous Retinal Detachment Following Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection. Korean Journal of Ophthalmology: KJO, 2009, 23, 124.	1.1	1
353	Intravitreal Bevacizumab for Treatment of Chronic Central Serous Chorioretinopathy. European Journal of Ophthalmology, 2009, 19, 613-617.	1.3	92
354	Anti-Vascular Endothelial Growth Factor Activity in the Bevacizumab and Triamcinolone Acetonide Combination for Intravitreal Use. European Journal of Ophthalmology, 2009, 19, 842-847.	1.3	3
355	Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema. Korean Journal of Ophthalmology: KJO, 2009, 23, 17.	1.1	24
356	Intravitreal Bevacizumab for Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 39-46.	1.3	58
357	rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector. , 2009, 50, 4279.		43
358	Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. British Journal of Ophthalmology, 2009, 93, 150-154.	3.9	93
359	Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation. British Journal of Ophthalmology, 2009, 93, 159-165.	3.9	7
360	Treatment of retinal diseases with VEGF antagonists. Progress in Brain Research, 2009, 175, 253-267.	1.4	43
361	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. , 2009, , CD007419.		61
362	Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. British Journal of Ophthalmology, 2009, 93, 1027-1032.	3.9	32
363	Short-term Results of a Single Intravitreal Bevacizumab (Avastin) Injection versus a Single Intravitreal Triamcinolone Acetonide (Kenacort) Injection for the Management of Refractory Noninfectious Uveitic Cystoid Macular Edema. Ocular Immunology and Inflammation, 2009, 17, 423-430.	1.8	39
364	The Boston Ocular Surface Prosthesis as a Novel Drug Delivery System for Bevacizumab. Seminars in Ophthalmology, 2009, 24, 149-155.	1.6	31
365	Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. British Journal of Ophthalmology, 2009, 93, 1353-1358.	3.9	29
366	Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit. , 2009, 50, 3233.		104
367	Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration. Ophthalmic Research, 2009, 41, 21-27.	1.9	20

#	Article	IF	Citations
368	Large Subretinal Haemorrhage following Change from Intravitreal Bevacizumab to Ranibizumab. Ophthalmologica, 2009, 223, 279-282.	1.9	22
369	Prevention and Treatment of Corneal Neovascularization: Comparison of Different Doses of Subconjunctival Bevacizumab with Corticosteroid in Experimental Rats. Ophthalmic Research, 2009, 42, 90-95.	1.9	25
370	Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. British Journal of Ophthalmology, 2009, 93, 754-758.	3.9	47
371	Intravitreal Bevacizumab (Avastin) for the Treatment of Cystoid Macular Edema in BehÃ§et Disease. Ocular Immunology and Inflammation, 2009, 17, 59-64.	1.8	32
372	Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. British Journal of Ophthalmology, 2009, 93, 914-919.	3.9	16
373	VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Current Opinion in Cell Biology, 2009, 21, 154-165.	5.4	636
374	Effects of intravitreal bevacizumab (AvastinÂ®) therapy on retrobulbar blood flow parameters in patients with neovascular ageâ€related macular degeneration. Journal of Clinical Ultrasound, 2010, 38, 66-70.	0.8	20
375	Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide). Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 35-42.	1.9	19
376	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1-11.	1.9	96
377	Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 541-548.	1.9	36
378	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 735-743.	1.9	83
379	Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1089-1094.	1.9	52
380	One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 899-906.	1.9	31
381	Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1031-1037.	1.9	13
382	Short- and long-term safety profile and efficacy of topical bevacizumab (AvastinÂ®) eye drops against corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1375-1382.	1.9	154
383	Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1601-1608.	1.9	59
384	Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1487-1492.	1.9	65
385	Comparison of UHR-OCT versus Stratus-OCT for definition of early retinal changes after intravitreal Bevacizumab (AvastinÂ®) application in patients with AMD. Spektrum Der Augenheilkunde, 2009, 23, 30-35.	0.3	0

#	Article	IF	Citations
386	Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up. Japanese Journal of Ophthalmology, 2009, 53, 125-130.	1.9	9
387	Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Japanese Journal of Ophthalmology, 2009, 53, 243-248.	1.9	36
388	Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri. International Ophthalmology, 2009, 29, 183-185.	1.4	17
389	Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. International Ophthalmology, 2009, 29, 411-413.	1.4	11
390	Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. International Ophthalmology, 2009, 29, 343-348.	1.4	16
391	Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. International Ophthalmology, 2009, 29, 349-357.	1.4	24
392	Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Documenta Ophthalmologica, 2009, 118, 81-88.	2.2	18
393	A multimodal approach to eye melanoma: patterns of care and related complications. Oncology Reviews, 2009, 3, 41-49.	1.8	0
394	Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series. Journal of Ocular Biology, Diseases, and Informatics, 2009, 2, 40-46.	0.2	4
395	Therapeutic Protein Kinase Inhibitors. Cellular and Molecular Life Sciences, 2009, 66, 1163-1177.	5.4	177
399	Bevacizumab: a new hope?. Eye, 2009, 23, 1755-1757.	2.1	0
400	Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye, 2009, 23, 117-123.	2.1	109
401	Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye, 2009, 23, 694-702.	2.1	47
402	Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review. Eye, 2009, 23, 530-535.	2.1	10
403	Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study. Eye, 2009, 23, 791-800.	2.1	1
404	Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. Eye, 2009, 23, 453-460.	2.1	19
405	Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture. Eye, 2009, 23, 2125-2126.	2.1	21
406	Intravitreal bevacizumab for macular edema secondary to retinal macroaneurysm. Eye, 2009, 23, 493-494.	2.1	30

#	Article	IF	Citations
407	Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma. Acta Ophthalmologica, 2009, 87, 100-101.	1.1	17
408	Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Australasian journal of optometry, The, 2009, 92, 34-37.	1.3	20
409	Macular pigment measurement in clinics: controlling the effect of the ageing media. Ophthalmic and Physiological Optics, 2009, 29, 338-344.	2.0	21
410	Subconjunctival Injection of Bevacizumab (Avastin) on Corneal Neovascularization in Different Rabbit Models of Corneal Angiogenesis. , 2009, 50, 1659.		74
411	The Combination of Intravitreal Bevacizumab and Phacoemulsification Surgery in Patients with Cataract and Coexisting Diabetic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 83-90.	1.4	37
412	Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Experimental Eye Research, 2009, 88, 522-527.	2.6	57
413	Diabetic Macular Edema: Pathogenesis and Treatment. Survey of Ophthalmology, 2009, 54, 1-32.	4.0	461
414	Bevacizumab (Avastin) for the Treatment of Ocular Disease. Survey of Ophthalmology, 2009, 54, 372-400.	4.0	125
415	Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies. Ophthalmology, 2009, 116, 286-296.e4.	5.2	70
416	Economic Implications of Current Age-Related Macular Degeneration Treatments. Ophthalmology, 2009, 116, 481-487.	5.2	27
417	Vitreous Mediators after Intravitreal Bevacizumab or Triamcinolone Acetonide in Eyes with Proliferative Diabetic Retinopathy. Ophthalmology, 2009, 116, 921-926.	5.2	75
418	Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2009, 116, 747-755.e1.	5.2	83
419	Analysis of the Effect of Intravitreal Bevacizumab Injection on Diabetic Macular Edema after Cataract Surgery. Ophthalmology, 2009, 116, 1151-1157.	5.2	94
420	Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. Ophthalmology, 2009, 116, 1488-1497.e1.	5.2	125
421	Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema. Ophthalmology, 2009, 116, 1481-1487.e1.	5.2	90
422	Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor. Ophthalmology, 2009, 116, 1748-1754.	5.2	36
423	Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration. Ophthalmology, 2009, 116, S1-S7.	5.2	166
424	Antiangiogenic Approaches to Age-Related Macular Degeneration Today. Ophthalmology, 2009, 116, S15-S23.	5.2	112

#	Article	IF	Citations
425	Outcome Measures to Assess Efficacy of Treatments for Age-Related Macular Degeneration. Ophthalmology, 2009, 116, S8-S14.	5.2	6
426	Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration. Journal of Cataract and Refractive Surgery, 2009, 35, 1518-1522.	1.5	26
427	Intravitreal Bevacizumab for Choroidal Neovascularization Attributable to Pathological Myopia: One-Year Results. American Journal of Ophthalmology, 2009, 147, 94-100.e1.	3.3	160
428	Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study. American Journal of Ophthalmology, 2009, 147, 1022-1030.e5.	3.3	37
429	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study. American Journal of Ophthalmology, 2009, 148, 59-65.e1.	3.3	71
430	Long-term Results of Intravitreal Bevacizumab Injection for Choroidal Neovascularization Secondary to Angioid Streaks. American Journal of Ophthalmology, 2009, 148, 584-590.e2.	3.3	56
431	Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Antiâ€“Vascular Endothelial Growth Factor Therapies. American Journal of Ophthalmology, 2009, 148, 647-656.	3.3	100
432	Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. American Journal of Ophthalmology, 2009, 148, 875-882.e1.	3.3	66
433	Three-dimensional ultrahigh resolution optical coherence tomography imaging of age-related macular degeneration. Optics Express, 2009, 17, 4046.	3.4	43
434	Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma. Optometry - Journal of the American Optometric Association, 2009, 80, 243-248.	0.6	9
435	Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration. Drugs and Aging, 2009, 26, 295-320.	2.7	27
436	Retinal Angiography and Optical Coherence Tomography. , 2009, , .		18
437	Intravitreal Combination of Triamcinolone Acetonide and Bevacizumab (Kenacort-Avastin) in Diffuse Diabetic Macular Edema. Seminars in Ophthalmology, 2009, 24, 225-230.	1.6	9
438	Topical Bevacizumab in the Treatment of Corneal Neovascularization. JAMA Ophthalmology, 2009, 127, 381.	2.4	182
439	Evaluation of the Sterility, Stability, and Efficacy of Bevacizumab Stored in Multiple-Dose Vials for 6 Months. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 65-70.	1.4	28
440	Functional Analysis of Platelet-Activating Factor in the Retinal Pigment Epithelial Cells and Choroidal Endothelial Cells. Current Eye Research, 2009, 34, 957-965.	1.5	13
441	Stem cell biology and cell transplantation therapy in the retina. Biotechnology and Genetic Engineering Reviews, 2009, 26, 297-334.	6.2	26
442	Evaluation of Differential Toxicity of Varying Doses of Bevacizumab on Retinal Ganglion Cells, Retinal Pigment Epithelial Cells, and Vascular Endothelial Growth Factorâ€“Enriched Choroidal Endothelial Cells. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 507-512.	1.4	25

#	Article	IF	Citations
443	Intravitreal bevacizumab for treatmentâ€naÃ¨ve subfoveal occult choroidal neovascularization in ageâ€related macular degeneration. Acta Ophthalmologica, 2009, 87, 404-407.	1.1	25
444	Efficacy of intravitreal bevacizumab (Avastin^{Â®}) therapy for early and advanced neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2009, 87, 611-617.	1.1	24
445	Intravitreal bevacizumab (Avastin^{Â®}) for neovascular ageâ€related macular degeneration in treatmentâ€naive patients. Acta Ophthalmologica, 2009, 87, 714-719.	1.1	24
446	Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmologica, 2009, 87, 683-684.	1.1	23
447	Combined intravitreal antiâ€vascular endothelial growth factor (Avastin^{Â®}) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmologica, 2010, 88, 610-613.	1.1	44
448	Effect of intravitreal bevacizumab (Avastin^{Â®}) in neovascular ageâ€related macular degeneration using a treatment regimen based on optical coherence tomography: 6â€and 12â€month results. Acta Ophthalmologica, 2010, 88, 594-600.	1.1	25
449	Intravitreal pegaptanib sodium (Macugen^{Â®}) for diabetic macular oedema. Acta Ophthalmologica, 2009, 87, 623-630.	1.1	42
450	Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Canadian Journal of Ophthalmology, 2009, 44, 451-456.	0.7	52
451	Retinopathy of Prematurity. Critical Care Nursing Clinics of North America, 2009, 21, 213-233.	0.8	8
452	Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). British Journal of Ophthalmology, 2009, 93, 457-462.	3.9	111
453	SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMA. Retina, 2009, 29, 33-37.	1.7	52
454	BEVACIZUMAB IS NOT TOXIC TO RETINAL GANGLION CELLS AFTER REPEATED INTRAVITREAL INJECTION. Retina, 2009, 29, 306-312.	1.7	24
455	VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 133-148.	1.7	30
456	EFFECT OF RANIBIZUMAB RETREATMENT FREQUENCY ON NEUROSENSORY RETINAL VOLUME IN NEOVASCULAR AMD. Retina, 2009, 29, 592-600.	1.7	13
457	TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 723-731.	1.7	170
458	BEVACIZUMAB IN MACULAR EDEMA. Retina, 2009, 29, 941-948.	1.7	4
459	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. Retina, 2009, 29, 875-912.	1.7	215
460	MACULAR HEMORRHAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER STABILIZATION WITH ANTIANGIOGENIC THERAPY. Retina, 2009, 29, 1074-1079.	1.7	17

#	Article	IF	Citations
461	COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 1067-1073.	1.7	45
462	SHORT-TERM EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB VERSUS RANIBIZUMAB INJECTIONS FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 1235-1241.	1.7	24
463	VASCULAR EVENTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAOCULAR BEVACIZUMAB. Retina, 2009, 29, 1404-1408.	1.7	12
464	EVALUATION OF SAFETY FOR BILATERAL SAME-DAY INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2009, 29, 1213-1217.	1.7	65
465	Bevacizumab for the Treatment of Corneal Neovascularization. Cornea, 2009, 28, S26-S30.	1.7	2
466	Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2009, 20, 158-165.	2.9	110
467	INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NAÃVE PATIENTS WITH SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 1227-1234.	1.7	14
468	INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. Retina, 2009, 29, 750-756.	1.7	91
469	Knowledge discovery in ophthalmology: analysis of wet form of age-related macular degeneration treatment outcomes. Proceedings of SPIE, 2009, , .	0.8	0
470	INTRAVITREAL INJECTION OF 2.5 mg VERSUS 1.25 mg BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD. Retina, 2009, 29, 319-324.	1.7	49
471	SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB. Retina, 2009, 29, 313-318.	1.7	114
472	Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. International Ophthalmology Clinics, 2009, 49, 95-107.	0.7	30
475	Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib. JAMA Ophthalmology, 2009, 127, 494.	2.4	76
476	Intravitreal Injection of Bevacizumab before Vitrectomy for Proliferative Diabetic Retinopathy. European Journal of Ophthalmology, 2009, 19, 848-852.	1.3	77
477	Balance between Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor in Diabetic Retinopathy. Frontiers in Diabetes, 2009, , 124-141.	0.4	1
478	VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, 1218-1226.	1.7	24
479	VITREOMACULAR TRACTION HINDERS THE EFFECTIVENESS OF ANTI-VEGF THERAPY IN A PATIENT WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retinal Cases and Brief Reports, 2009, 3, 310-312.	0.6	0
480	BEVACIZUMAB COMPARED WITH MACULAR LASER GRID PHOTOCOAGULATION FOR CYSTOID MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION. Retina, 2009, 29, 511-515.	1.7	119

#	Article	IF	Citations
481	SHORT-TERM FLUCTUATION OF DIABETIC MACULAR EDEMA AFTER INTRAVITREAL RANIBIZUMAB INJECTION. Retina, 2009, 29, 1274-1281.	1.7	12
482	INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE. Retina, 2009, 29, 1134-1140.	1.7	52
483	CLINICAL CHARACTERISTICS OF ENDOPHTHALMITIS AFTER AN INJECTION OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR. Retina, 2010, 30, 1051-1057.	1.7	50
484	PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION. Retina, 2010, 30, 1350-1367.	1.7	142
485	Intravitreous Bevacizumab Injection. JAMA Ophthalmology, 2010, 128, 884.	2.4	12
486	AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF PEGAPTANIB OR RANIBIZUMAB IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION. Retina, 2010, 30, 1034-1038.	1.7	22
487	RESULTS OF 1-YEAR FOLLOW-UP EXAMINATIONS AFTER INTRAVITREAL BEVACIZUMAB ADMINISTRATION FOR IDIOPATHIC CHOROIDAL NEOVASCULARIZATION. Retina, 2010, 30, 733-738.	1.7	26
488	INTRAVITREAL BEVACIZUMAB IN VASCULAR PIGMENT EPITHELIUM DETACHMENT AS A RESULT OF SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2010, 30, 1420-1425.	1.7	29
489	The Effect of Subconjunctival Suramin on Corneal Neovascularization in Rabbits. Cornea, 2010, 29, 86-92.	1.7	25
490	SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FOR IMAGING ERM, RETINAL EDEMA, AND VITREOMACULAR INTERFACE. Retina, 2010, 30, 246-253.	1.7	26
491	EFFECT OF PHOTODYNAMIC THERAPY ALONE OR COMBINED WITH POSTERIOR SUBTENON TRIAMCINOLONE ACETONIDE OR INTRAVITREAL BEVACIZUMAB ON CHOROIDAL HYPOFLUORESCENCE BY INDOCYANINE GREEN ANGIOGRAPHY. Retina, 2010, 30, 495-502.	1.7	17
492	THE RESULTS OF INTRAVITREAL BEVACIZUMAB INJECTIONS FOR PERSISTENT NEOVASCULARIZATIONS IN PROLIFERATIVE DIABETIC RETINOPATHY AFTER PHOTOCOAGULATION THERAPY. Retina, 2010, 30, 570-577.	1.7	26
493	INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF SUBRETINAL FLUID ASSOCIATED WITH CHOROIDAL OSTEOMA. Retina, 2010, 30, 945-951.	1.7	42
494	POSITIVE RESPONSE TO INTRAVITREAL RANIBIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY. Retina, 2010, 30, 1400-1404.	1.7	28
495	INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2010, 30, 1426-1431.	1.7	8
496	AQUEOUS HUMOR AND PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND INTERLEUKIN-8 IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2010, 30, 1465-1471.	1.7	80
497	In Vitro Effects of Antivascular Endothelial Growth Factors on Cultured Human Trabecular Meshwork Cells. Journal of Glaucoma, 2010, 19, 437-441.	1.6	52
498	LONG-TERM OUTCOMES OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION IN PSEUDOXANTHOMA ELASTICUM. Retina, 2010, 30, 748-755.	1.7	61

#	Article	IF	Citations
499	INTRAVITREAL BEVACIZUMAB DURING PREGNANCY. Retina, 2010, 30, 1405-1411.	1.7	83
500	INTRAVITREAL BEVACIZUMAB ALONE VERSUS COMBINED VERTEPORFIN PHOTODYNAMIC THERAPY AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2010, 30, 548-554.	1.7	17
501	Perilimbal Bevacizumab Injection for Interface Neovascularization After Deep Anterior Lamellar Keratoplasty. Cornea, 2010, 29, 1268-1272.	1.7	14
502	Use of Retinal Procedures in Medicare Beneficiaries From 1997 to 2007. JAMA Ophthalmology, 2010, 128, 1335.	2.4	95
503	Corneal Graft Surgery Combined with Subconjunctival Bevacizumab (Avastin). Cornea, 2010, 29, 691-693.	1.7	21
504	Experience with Intravitreal Bevacizumab as a Preoperative Adjunct in 23-G Vitrectomy for Advanced Proliferative Diabetic Retinopathy. European Journal of Ophthalmology, 2010, 20, 1047-1052.	1.3	46
505	The effects of intravitreally injected bevacizumab on the retina and retina pigment epithelium: experimental in-vivo electron microscopic study in intact versus vitrectomized eyes. Open Medicine (Poland), 2010, 5, 745-751.	1.3	1
506	Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 467-476.	1.9	29
507	Surgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 37-47.	1.9	46
508	Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 641-650.	1.9	35
509	Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 635-640.	1.9	33
510	Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 779-784.	1.9	22
511	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 785-791.	1.9	96
512	Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Japanese Journal of Ophthalmology, 2010, 54, 310-319.	1.9	39
513	Intravitreal bevacizumab for age-related macular degeneration with good visual acuity. Japanese Journal of Ophthalmology, 2010, 54, 565-570.	1.9	14
514	Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2010, 54, 571-577.	1.9	29
515	Role of intravitreal bevacizumab in the management of Ealesâ€™ disease. International Ophthalmology, 2010, 30, 57-61.	1.4	25
516	Successful treatment of choroidal neovascular membrane in retinitis pigmentosa with intravitreal bevacizumab. International Ophthalmology, 2010, 30, 425-428.	1.4	24

#	Article	IF	Citations
517	Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular ageâ€related macular degeneration in an Australian population. Clinical and Experimental Ophthalmology, 2010, 38, 659-663.	2.6	9
518	Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clinical and Experimental Ophthalmology, 2010, 38, 875-884.	2.6	15
519	Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygenâ€induced retinopathy. Glia, 2010, 58, 43-54.	4.9	116
520	The inhibition of advanced glycation end-products-induced retinal vascular permeability by silver nanoparticles. Biomaterials, 2010, 31, 2260-2271.	11.4	48
523	Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye, 2010, 24, 203-213.	2.1	23
524	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye, 2010, 24, 816-824.	2.1	38
525	Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye, 2010, 24, 1708-1715.	2.1	71
526	Patients’ knowledge and perspectives on wet age-related macular degeneration and its treatment. Clinical Ophthalmology, 2010, 4, 375.	1.8	13
527	Comparison of Intravitreal Triamcinolone Versus Bevacizumab in Bilateral Diabetic Macular Edema by Optical Coherence Tomography (OCT) Patterns. Journal of Korean Ophthalmological Society, 2010, 51, 210.	0.2	3
528	Corneal Endothelial Change After Intravitreal Bevacizumab Injection. Journal of Korean Ophthalmological Society, 2010, 51, 1549.	0.2	2
529	Three-Monthly Intravitreal Bevacizumab Injections for Neovascular Age-Related Macular Degeneration: Short-Term Visual Acuity Results. European Journal of Ophthalmology, 2010, 20, 740-744.	1.3	5
530	Antifibrotic Activity of Bevacizumab on Human Tenon's Fibroblasts In Vitro. , 2010, 51, 6524.		68
531	Macular Hole Following Intravitreal Ranibizumab Injections for Choroidal Neovascularization. Journal of Korean Ophthalmological Society, 2010, 51, 774.	0.2	2
532	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. Clinical Ophthalmology, 2010, 4, 275.	1.8	16
533	Causes of interruption of bevacizumab therapy in age-related macular degeneration. Arquivos Brasileiros De Oftalmologia, 2010, 73, 146-149.	0.5	9
534	The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy. Korean Journal of Ophthalmology: KJO, 2010, 24, 155.	1.1	61
535	Choroidal neovascularization secondary to inflammation, infection, and myopia. , 2010, , 162-169.		1
536	Herpetic keratitis. , 2010, , 91-97.		7

#	Article	IF	Citations
537	Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?. Clinical Ophthalmology, 2010, 4, 307.	1.8	8
538	Pathophysiology of vascular endothelial growth factor and other angiogenic molecules. , 2010, , 230-235.		0
539	Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2226.	0.4	0
540	The Effect of Bevacizumab on Corneal Neovascularization in Rabbits. Korean Journal of Ophthalmology: KJO, 2010, 24, 230.	1.1	23
541	The Different Effects of Early and Late Bevacizumab (Avastin) Injection on Inhibiting Corneal Neovascularization and Conjunctivalization in Rabbit Limbal Insufficiency. , 2010, 51, 6277.		50
542	REPEATED NONINFECTIOUS ENDOPHTHALMITIS AFTER INTRAVITREAL ADMINISTRATION OF BEVACIZUMAB: A REPORT OF TWO CASES. Retinal Cases and Brief Reports, 2010, 4, 220-223.	0.6	2
543	REBOUND NEOVASCULARIZATION DURING BEVACIZUMAB THERAPY. Retinal Cases and Brief Reports, 2010, 4, 216-219.	0.6	1
544	Features of Optical Coherence Tomography Are Predictive of Visual Outcomes after Intravitreal Bevacizumab Injection for Diabetic Macular Edema. Ophthalmologica, 2010, 224, 374-380.	1.9	41
545	Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema. Ophthalmologica, 2010, 224, 258-264.	1.9	25
546	Identifying and Eliminating the Roadblocks to Comparative-Effectiveness Research. New England Journal of Medicine, 2010, 363, 105-107.	27.0	37
547	A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. British Journal of Ophthalmology, 2010, 94, 174-179.	3.9	29
548	Phospholipase Cî³ Activation Drives Increased Production of Autotaxin in Endothelial Cells and Lysophosphatidic Acid-Dependent Regression. Molecular and Cellular Biology, 2010, 30, 2401-2410.	2.3	35
549	Bevacizumab vs Photodynamic Therapy for Choroidal Neovascularization in Multifocal Choroiditis. JAMA Ophthalmology, 2010, 128, 1100.	2.4	38
550	Update on combination therapy in wet age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 681-688.	0.6	1
551	Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study. Expert Review of Clinical Pharmacology, 2010, 3, 747-752.	3.1	5
552	Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral Envelope Proteins. Human Gene Therapy, 2010, 21, 199-209.	2.7	38
553	Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 799-809.	0.6	0
554	Intravitreal Bevacizumab (Avastin) in the Treatment of Macular Edema Associated With Perfused Retinal Vein Occlusion. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 85-90.	1.4	14

#	Article	IF	Citations
555	Neovascular age-related macular degeneration and anti-VEGF nonresponders. Expert Review of Ophthalmology, 2010, 5, 35-41.	0.6	5
556	Choroidal Neovascular Membranes Express Toll-Like Receptor 3. Ophthalmic Research, 2010, 44, 237-241.	1.9	17
557	Juxtafoveal Choroidal Neovascularization Secondary to Persistent Placoid Maculopathy Treated with Intravitreal Bevacizumab. Ocular Immunology and Inflammation, 2010, 18, 399-401.	1.8	13
558	Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema: Early Results. TÃ¼rk Oftalmoloji Dergisi, 2010, 40, 145-150.	0.9	0
559	Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. British Journal of Ophthalmology, 2010, 94, 1215-1218.	3.9	129
560	Effect of intravitreal bevacizumab (AvastinÂ®) in the fellow eye of a patient with bilateral exudative age related macular degeneration. Scottish Medical Journal, 2010, 55, 58-58.	1.3	0
561	Routes for drug deliverytopical, transscleral, suprachoroidal, and intravitreal gas-phase nanoparticles. , 2010, , 74-80.		0
562	Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. Developments in Ophthalmology, 2010, 46, 21-38.	0.1	15
563	Applications of Nanobiotechnology in Ophthalmology â€“ Part I. Ophthalmic Research, 2010, 44, 1-16.	1.9	9
564	Effects of Bevacizumab on Apoptosis, Na⁺-K⁺-Adenosine Triphosphatase and Zonula Occludens 1 Expression on Cultured Corneal Endothelial Cells. Ophthalmic Research, 2010, 44, 43-49.	1.9	7
565	Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ: British Medical Journal, 2010, 340, c2459-c2459.	2.3	186
566	Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications. Mediators of Inflammation, 2010, 2010, 1-14.	3.0	170
567	Long-Term Follow-Up After Multiple Intravitreal Bevacizumab Injections for Exudative Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 79-84.	1.4	14
568	Anti-VEGF agents for age-related macular degeneration. Expert Opinion on Therapeutic Patents, 2010, 20, 103-118.	5.0	31
570	Influence of Non-Toxic Doses of Bevacizumab and Ranibizumab on Endothelial Functions and Inhibition of Angiogenesis. Current Eye Research, 2010, 35, 835-841.	1.5	8
571	Cytokine Binding by Polysaccharideâ^'Antibody Conjugates. Molecular Pharmaceutics, 2010, 7, 1769-1777.	4.6	11
572	Corneal transparency: Genesis, maintenance and dysfunction. Brain Research Bulletin, 2010, 81, 198-210.	3.0	150
573	Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration. Ophthalmology, 2010, 117, 298-302.	5.2	90

#	Article	IF	Citations
574	Severe Intraocular Inflammation after Intravitreal Injection of Bevacizumab. Ophthalmology, 2010, 117, 512-516.e2.	5.2	68
575	Progression of Geographic Atrophy and Genotype in Age-Related Macular Degeneration. Ophthalmology, 2010, 117, 1554-1559.e1.	5.2	75
576	Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study. Ophthalmology, 2010, 117, 1974-1981.e1.	5.2	34
577	A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2010, 117, 2134-2140.	5.2	264
578	Intravitreal bevacizumab for posterior capsule neovascularization. Saudi Journal of Ophthalmology, 2010, 24, 63-65.	0.3	1
579	Two-Year Visual Results for Older Asian Women Treated With Photodynamic Therapy or Bevacizumab for Myopic Choroidal Neovascularization. American Journal of Ophthalmology, 2010, 149, 140-146.e1.	3.3	71
580	Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy. American Journal of Ophthalmology, 2010, 149, 947-954.e1.	3.3	65
581	Efficacy of Intravitreal Bevacizumab Combined With Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. American Journal of Ophthalmology, 2010, 150, 48-54.e1.	3.3	90
582	Histopathology of Neovascular Tissue From Eyes With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab Injection. American Journal of Ophthalmology, 2010, 150, 223-229.e1.	3.3	56
583	Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF) Tj ETQq1 1 0.784314 rgBT /Ov	3.3	88
584	Ultrasound assessment of shortâ€term ocular vascular effects of intravitreal injection of bevacizumab (Avastin^{Â®}) in neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2010, 88, 641-645.	1.1	47
585	Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmologica, 2010, 88, 868-871.	1.1	32
586	Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the longâ€term observation of nonâ€treated eyes. Acta Ophthalmologica, 2010, 88, e107-14.	1.1	16
587	Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. Acta Ophthalmologica, 2010, 88, e305-10.	1.1	9
588	Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. Canadian Journal of Ophthalmology, 2010, 45, 501-508.	0.7	8
589	Intraocular Properties of a Repository Urokinase Receptor Antagonist Ã…36 Peptide in Rabbits. Current Eye Research, 2010, 35, 742-750.	1.5	1
590	Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 105-110.	1.4	148
591	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.6	1

#	Article	IF	Citations
592	Severe Corneal Changes following Intravitreal Injection of Bevacizumab. Ocular Immunology and Inflammation, 2010, 18, 268-274.	1.8	21
593	Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration. BioDrugs, 2010, 24, 183-194.	4.6	50
594	Comparing Treatment of Neovascular Age-related Macular Degeneration with Sequential Intravitreal Avastin and Macugen Versus Intravitreal Mono-therapyâ€“A Pilot Study. Current Eye Research, 2011, 36, 958-963.	1.5	8
595	Radiation therapy in the treatment of exudative age-related macular degeneration. Expert Review of Ophthalmology, 2011, 6, 323-337.	0.6	1
596	Bilateral Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration: Effect of Baseline Visual Acuity. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 401-405.	1.4	5
597	Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration in Clinical Practice. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 467-470.	1.4	8
598	Management of Neovascular AMD. , 2011, , 79-98.		0
599	Combined scraping, coagulation, and subconjunctival bevacizumab in corneal transplantation for bullous keratopathy with corneal neovascularization. Taiwan Journal of Ophthalmology, 2011, 1, 21-24.	0.7	1
600	Retinal pigment epithelium tears after bevacizumab injection. Optometry - Journal of the American Optometric Association, 2011, 82, 152-157.	0.6	4
601	Drug Product Development for the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , .	0.6	13
602	Endophthalmitis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Neovascular Age-Related Macular Degeneration. Seminars in Ophthalmology, 2011, 26, 139-148.	1.6	21
603	Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Canadian Journal of Ophthalmology, 2011, 46, 182-185.	0.7	18
604	Clinicopathologic Correlation of Choroidal and Retinal Neovascular Lesions in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2011, 151, 161-169.	3.3	38
605	Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File. American Journal of Ophthalmology, 2011, 151, 887-895.e1.	3.3	122
606	How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact Clinical Care. American Journal of Ophthalmology, 2011, 152, 509-514.	3.3	18
607	Comparing protein VEGF inhibitors: In vitro biological studies. Biochemical and Biophysical Research Communications, 2011, 408, 276-281.	2.1	82
608	Effects of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Exudative Age-Related Macular Degeneration. Ophthalmology, 2011, 118, 101-110.	5.2	85
609	The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing. Ophthalmology, 2011, 118, 1098-1106.	5.2	143

#	Article	IF	Citations
610	Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization. Acta Ophthalmologica, 2011, 89, 459-462.	1.1	21
611	Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmologica, 2011, 89, 647-653.	1.1	20
612	Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. Acta Ophthalmologica, 2011, 89, 641-646.	1.1	23
613	Short-term effects of intravitreal bevacizumab (Avastin^{Â®}) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmologica, 2011, 89, e41-e45.	1.1	21
614	Decreased prothrombin time after intravitreal bevacizumab in the early period in patients with proliferative diabetic retinopathy. Acta Ophthalmologica, 2011, 89, e332-5.	1.1	5
615	Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine, 2011, 364, 1897-1908.	27.0	2,355
616	Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma. Clinical Ophthalmology, 2011, 5, 1051.	1.8	18
618	Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?. Medical Journal of Australia, 2011, 194, 567-568.	1.7	9
619	Adverse skin reactions following intravitreal bevacizumab injection. BMJ Case Reports, 2011, 2011, bcr0220102753-bcr0220102753.	0.5	3
620	Effect of Focal and Grid Pattern PASCAL Photocoagulation Treatment in Diabetic Macular Edema. Journal of Korean Ophthalmological Society, 2011, 52, 197.	0.2	0
621	Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer. Clinical Ophthalmology, 2011, 5, 1217.	1.8	7
622	Lasting Controversy on Ranibizumab and Bevacizumab. Theranostics, 2011, 1, 395-402.	10.0	33
623	Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy. Journal of Ophthalmology, 2011, 2011, 1-10.	1.3	5
624	Comparison of the Effects Between Bevacizumab and Mitomycin C on the Survival of Fibroblasts. Journal of Korean Ophthalmological Society, 2011, 52, 345.	0.2	3
625	Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. Journal of Ophthalmology, 2011, 2011, 1-13.	1.3	44
626	Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2011, 25, 161.	1.1	8
627	Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2011, 25, 231.	1.1	8
628	POSTERIOR VITREOUS DETACHMENT WITH MICROPLASMIN ALTERS THE RETINAL PENETRATION OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN RABBIT EYES. Retina, 2011, 31, 393-400.	1.7	22

#	Article	IF	Citations
629	INTRAVITREAL BEVACIZUMAB VERSUS COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2011, 31, 1819-1826.	1.7	19
630	SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB. Retina, 2011, 31, 1028-1035.	1.7	94
631	Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization. Cornea, 2011, 30, 1110-1114.	1.7	36
632	THE ROLE OF INTRAVITREAL BEVACIZUMAB IN EXPERIMENTAL POSTERIOR PENETRATING EYE INJURY. Retina, 2011, 31, 154-160.	1.7	5
633	The Effect of Methotrexate on Corneal Neovascularization in Rabbits. Cornea, 2011, 30, 442-446.	1.7	54
634	Preferred therapies for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2011, 22, 199-204.	2.9	36
635	Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration. Current Drug Targets, 2011, 12, 149-172.	2.1	56
636	EFFICACY AND SAFETY OF INTRAVITREAL BEVACIZUMAB COMPARED WITH INTRAVITREAL AND POSTERIOR SUB-TENON TRIAMCINOLONE ACETONIDE FOR TREATMENT OF UVEITIC CYSTOID MACULAR EDEMA. Retina, 2011, 31, 111-118.	1.7	75
637	A RETROSPECTIVE ANALYSIS OF TRIPLE COMBINATION THERAPY WITH INTRAVITREAL BEVACIZUMAB, POSTERIOR SUB-TENON'S TRIAMCINOLONE ACETONIDE, AND LOW-FLUENCE VERTEPORFIN PHOTODYNAMIC THERAPY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2011, 31, 446-452.	1.7	16
638	PROGNOSTI IMPLICATIONS OF PIGMENT EPITHELIAL DETACHMENT IN BEVACIZUMAB (AVASTIN)-TREATED EYES WITH AGE-RELATED MACULAR DEGENERATION AND CHOROIDAL NEOVASCULARIZATION. Retina, 2011, 31, 1812-1818.	1.7	30
639	Diabetic Papillopathy: Current and New Treatment Options. Current Diabetes Reviews, 2011, 7, 171-175.	1.3	43
640	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Retina, 2011, 31, 1449-1469.	1.7	131
641	Photodynamic Therapy With Verteporfin Combined With Subconjunctival Injection of Bevacizumab for Corneal Neovascularization. Cornea, 2011, 30, 30-33.	1.7	24
642	Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration. Current Drug Targets, 2011, 12, 173-181.	2.1	95
643	Pseudoxanthoma elasticum, ocular manifestations, complications and treatment. Australasian journal of optometry, The, 2011, 94, 169-180.	1.3	66
644	Ranibizumab in the treatment of choroidal neovascularisation due to ageâ€related macular degeneration: an optical coherence tomography and multifocal electroretinography study. Australasian journal of optometry, The, 2011, 94, 268-275.	1.3	8
645	Solution Formulation Development of a VEGF Inhibitor for Intravitreal Injection. AAPS PharmSciTech, 2011, 12, 362-371.	3.3	8
646	Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 273-280.	1.9	9

#	Article	IF	Citations
647	Safety threshold of intravitreal activated protein-C. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 833-838.	1.9	3
648	Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 1295-1301.	1.9	14
649	Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 1547-1552.	1.9	14
650	Negative correlation between aqueous vascular endothelial growth factor levels and axial length. Japanese Journal of Ophthalmology, 2011, 55, 401-404.	1.9	35
651	VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Japanese Journal of Ophthalmology, 2011, 55, 435-443.	1.9	32
652	Microvascular Modifications in Diabetic Retinopathy. Current Diabetes Reports, 2011, 11, 253-264.	4.2	170
653	AltersabhÃngige Makuladegeneration. , 2011, , .		3
655	Intraocular Pharmacokinetics of a Crystalline Lipid Prodrug, Octadecyloxyethyl-Cyclic-Cidofovir, for Cytomegalovirus Retinitis. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 157-162.	1.4	7
656	Intravitreal Bevacizumab Injection Therapy for Persistent Macular Edema After Idiopathic Macular Epiretinal Membrane Surgery. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 287-292.	1.4	14
657	Injection Site and Pharmacokinetics After Intravitreal Injection of Immunoglobulin G. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 35-41.	1.4	3
658	Evaluation of the Incidence of Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. Ophthalmologica, 2011, 226, 145-150.	1.9	38
659	Intravitreal Injection of 2.5â€‰mg Bevacizumab for Treatment of Myopic Choroidal Neovascularization in Treatment-Naive Cases: A 2-Year Follow-Up. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 395-400.	1.4	18
660	Effects of Intravitreally Injected Bevacizumab on Vascular Endothelial Growth Factor in Fellow Eyes. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 379-383.	1.4	27
661	Vascular endothelial growth factor inhibition in uveitis: a systematic review. British Journal of Ophthalmology, 2011, 95, 162-165.	3.9	45
662	Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab. Human Gene Therapy, 2011, 22, 1525-1535.	2.7	24
663	Corneal Penetration of Topical and Subconjunctival Bevacizumab. , 2011, 52, 8718.		111
664	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab with Fluid-Air Exchange. Seminars in Ophthalmology, 2011, 26, 25-27.	1.6	7
665	Intravitreal bevacizumab as a primary treatment for idiopathic choroidal neovascularization. Middle East African Journal of Ophthalmology, 2011, 18, 220.	0.3	3

#	Article	IF	Citations
666	Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration. Ophthalmic Research, 2011, 45, 129-134.	1.9	20
667	Effects of Bevacizumab (AvastinÂ®) on the Electroretinogram of Isolated Rat Retina. Ophthalmic Research, 2011, 46, 145-151.	1.9	2
668	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Current Vascular Pharmacology, 2011, 9, 629-646.	1.7	39
669	Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing. British Journal of Ophthalmology, 2011, 95, 1419-1423.	3.9	26
670	Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 219-224.	1.4	57
671	Combined intravitreal bevacizumab with phacoemulsification in visually significant cataract and visually significant exudative maculopathy. Oman Journal of Ophthalmology, 2011, 4, 10.	0.3	1
672	Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian Journal of Ophthalmology, 2011, 59, 191.	1.1	59
673	Avastin Treatment Reduces Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity. Current Eye Research, 2012, 37, 624-629.	1.5	18
674	Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2012, 96, 394-399.	3.9	34
675	Bilateral acute macular neuroretinopathy in a postpartum, otherwise healthy female: A case report. Indian Journal of Ophthalmology, 2012, 60, 313.	1.1	8
676	Therapeutic Interventions against Inflammatory and Angiogenic Mediators in Proliferative Diabetic Retinopathy. Mediators of Inflammation, 2012, 2012, 1-10.	3.0	73
677	Managing bevacizumab-induced intraocular inflammation. Indian Journal of Ophthalmology, 2012, 60, 311.	1.1	6
678	INTRAOCULAR BEVACIZUMAB LEVELS 24 HOURS AFTER INTRAVITREAL INJECTION IN A NORMAL EYE. Retinal Cases and Brief Reports, 2012, 6, 65-68.	0.6	2
679	Intravitreal Bevacizumab After Intravitreal Triamcinolone for Exudative Age-Related Macular Degeneration. Asia-Pacific Journal of Ophthalmology, 2012, 1, 140-141.	2.5	0
680	Preferred therapies for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2012, 23, 182-188.	2.9	43
681	Diabetic Retinopathy: Current and New Treatment Options. Current Diabetes Reviews, 2012, 8, 32-41.	1.3	30
682	Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye, 2012, 26, 1099-1105.	2.1	69
683	High-dose ranibizumab therapy for vascularized pigment epithelial detachment. Eye, 2012, 26, 882-885.	2.1	11

#	Article	IF	Citations
684	Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. British Journal of Ophthalmology, 2012, 96, 14-20.	3.9	159
685	Focal Macular Electroretinograms after Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration. , 2012, 53, 4185.		14
686	Photodynamic therapy with verteporfin for corneal neovascularization. Middle East African Journal of Ophthalmology, 2012, 19, 185.	0.3	15
687	Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model. Ophthalmic Research, 2012, 48, 118-123.	1.9	23
688	Comparison of Age-Related Macular Degeneration Treatment Trials. Retina, 2012, Publish Ahead of Print, 413-6.	1.7	1
689	RETREATMENT WITH ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 1471-1479.	1.7	7
690	ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 4-9.	1.7	56
691	Effects of Subconjunctival Bevacizumab on Corneal Neovascularization. Cornea, 2012, 31, 937-944.	1.7	24
692	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL NEVUS. Retina, 2012, 32, 60-67.	1.7	19
693	LOC387715/HTRA1 VARIANTS AND THE RESPONSE TO COMBINED PHOTODYNAMIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2012, 32, 299-307.	1.7	23
694	Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease. Cornea, 2012, 31, 322-334.	1.7	30
695	Treatment of Pterygium by Ligation and Bevacizumab Injection. Cornea, 2012, 31, 1339-1341.	1.7	6
697	Discovering Drug Targets for Cancer Therapy. , 2012, , 299-322.		0
698	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 2012, 12, 1299-1313.	3.1	48
699	Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin). Ocular Surface, 2012, 10, 67-83.	4.4	138
700	Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. Canadian Journal of Ophthalmology, 2012, 47, 165-169.	0.7	9
701	Bevacizumab for Neovascular Age-related Macular Degeneration in China. Ophthalmology, 2012, 119, 2087-2093.	5.2	18
702	Optical Coherence Tomography Grading Reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2012, 119, 2549-2557.	5.2	59

#	Article	IF	Citations
703	Investigational VEGF antagonists for psoriasis. Expert Opinion on Investigational Drugs, 2012, 21, 33-43.	4.1	32
704	Extended Release of Bevacizumab by Thermosensitive Biodegradable and Biocompatible Hydrogel. Biomacromolecules, 2012, 13, 40-48.	5.4	109
705	Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity. American Journal of Ophthalmology, 2012, 153, 327-333.e1.	3.3	295
706	Intravitreal Bevacizumab for Treatment of Subfoveal Idiopathic Choroidal Neovascularization: Results of a 1-Year Prospective Trial. American Journal of Ophthalmology, 2012, 153, 300-306.e1.	3.3	33
707	Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact. American Journal of Ophthalmology, 2012, 153, 468-473.e1.	3.3	71
708	Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration. American Journal of Ophthalmology, 2012, 153, 678-686.e2.	3.3	119
709	Succinate Increases in the Vitreous Fluid of Patients With Active Proliferative Diabetic Retinopathy. American Journal of Ophthalmology, 2012, 153, 896-902.e1.	3.3	18
710	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. , 2012, 12, CD007419.		75
711	Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-Up. Ophthalmologica, 2012, 228, 78-83.	1.9	27
712	Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics, 2012, 13, 1037-1053.	1.3	27
713	Predictive Models of Choroidal Neovascularization and Geographic Atrophy Incidence Applied to Clinical Trial Design. American Journal of Ophthalmology, 2012, 154, 568-578.e12.	3.3	11
714	Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and Intravitreal Biologics for Ocular Inflammation. American Journal of Ophthalmology, 2012, 154, 429-435.e2.	3.3	15
715	Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization. American Journal of Ophthalmology, 2012, 154, 940-948.e1.	3.3	44
716	Corneal Neovascularization: An Anti-VEGF Therapy Review. Survey of Ophthalmology, 2012, 57, 415-429.	4.0	304
717	Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells. PLoS ONE, 2012, 7, e33456.	2.5	26
718	Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab. Journal of Korean Medical Science, 2012, 27, 1580.	2.5	19
719	New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration. Journal of Ophthalmology, 2012, 2012, 1-7.	1.3	15
720	Treatment of Neovascular Age Related Macular Degeneration. , 2012, , .		0

#	Article	IF	Citations
721	Anti-VEGF Treatment Strategies for Wet AMD. Journal of Ophthalmology, 2012, 2012, 1-7.	1.3	149
722	Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration. Open Ophthalmology Journal, 2012, 6, 54-58.	0.2	87
723	A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Clinical Ophthalmology, 2012, 6, 1519.	1.8	13
724	Wet Age Related Macular Degeneration. , 0, , .		1
725	Recent Advances in Ocular Nucleic Acid-Based Therapies: The Silent Era. , 0, , .		2
726	Promising Treatment Strategies for Neovascular AMD: Anti-VEGF Therapy. , 0, , .		0
727	Bevacizumab and Rapamycin Can Decrease Corneal Opacity and Apoptotic Keratocyte Number following Photorefractive Keratectomy. , 2012, 53, 7645.		10
728	Intrastromal injection of bevacizumab in patients with corneal neovascularization. Arquivos Brasileiros De Oftalmologia, 2012, 75, 277-279.	0.5	15
729	Retinopathy of prematurityâ€"promising newer modalities of treatment. Indian Pediatrics, 2012, 49, 139-143.	0.4	11
730	Vision, Retinal Thickness, and Foveal Avascular Zone Size After Intravitreal Bevacizumab for Diabetic Macular Edema. Advances in Therapy, 2012, 29, 359-369.	2.9	23
731	Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 989-997.	1.9	15
732	The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 1161-1167.	1.9	8
733	Costâ€utility analysis of bevacizumab versus ranibizumab in neovascular ageâ€related macular degeneration using a Markov model. Journal of Evaluation in Clinical Practice, 2012, 18, 247-255.	1.8	36
734	Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50â€ƒyears or older: 1â€year results of a prospective clinical study. Acta Ophthalmologica, 2012, 90, 61-67.	1.1	32
735	Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: A Prospective Study. Acta Ophthalmologica, 2012, 90, 254-258.	1.1	29
736	An evaluation of a novel instrument for measuring macular pigment optical density: the MPS 9000. Acta Ophthalmologica, 2012, 90, e90-7.	1.1	19
737	Comparison of the use of 5â€fluorouracil and bevacizumab in primary trabeculectomy: results at 1â€ƒyear. Clinical and Experimental Ophthalmology, 2012, 40, e135-42.	2.6	35
738	Regulation of cellâ€mediated collagen gel contraction in human retinal pigment epithelium cells by vascular endothelial growth factor compared with transforming growth factorâ€î²2. Clinical and Experimental Ophthalmology, 2012, 40, e76-86.	2.6	11

#	Article	IF	Citations
739	The role of glia in retinal vascular disease. Australasian journal of optometry, The, 2012, 95, 266-281.	1.3	107
740	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. Journal of Neuro-Oncology, 2012, 106, 81-88.	2.9	17
741	Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization. Clinical and Experimental Ophthalmology, 2013, 41, 63-72.	2.6	8
742	Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1073-1080.	1.9	18
744	Intravitreal bevacizumab for pigment epithelial detachments in age-related macular degeneration. Spektrum Der Augenheilkunde, 2013, 27, 184-195.	0.3	0
745	Successful treatment of melanocytoma associated choroidal neovascular membrane with intravitreal bevacizumab. Saudi Journal of Ophthalmology, 2013, 27, 117-119.	0.3	8
746	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. Saudi Journal of Ophthalmology, 2013, 27, 55-57.	0.3	6
747	Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 122-129.	5.2	268
748	Girdin and Its Phosphorylation Dynamically Regulate Neonatal Vascular Development and Pathological Neovascularization in the Retina. American Journal of Pathology, 2013, 182, 586-596.	3.8	23
749	COMPARATIVE EFFECTIVENESS OF ANTI-VEGF AGENTS FOR DIABETIC MACULAR EDEMA. International Journal of Technology Assessment in Health Care, 2013, 29, 392-401.	0.5	16
750	The angiopoietin:Tie 2 interaction: A potential target for future therapies in human vascular disease. Cytokine and Growth Factor Reviews, 2013, 24, 579-592.	7.2	89
751	The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. International Ophthalmology, 2013, 33, 507-513.	1.4	12
752	Photodynamic therapy for polypoidal choroidal vasculopathy. Progress in Retinal and Eye Research, 2013, 37, 182-199.	15.5	82
753	Age-related macular degeneration (AMD): Current concepts in pathogenesis and prospects for treatment. Tissue Engineering and Regenerative Medicine, 2013, 10, 164-175.	3.7	3
754	Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Japanese Journal of Ophthalmology, 2013, 57, 211-220.	1.9	11
755	Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Japanese Journal of Ophthalmology, 2013, 57, 63-67.	1.9	28
756	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. Taiwan Journal of Ophthalmology, 2013, 3, 128-133.	0.7	3
757	Diffusion of Technologies for the Care of Older Adults WithÂExudative Age-Related Macular Degeneration. American Journal of Ophthalmology, 2013, 155, 688-696.e2.	3.3	20

#	Article	IF	Citations
758	Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors. American Journal of Ophthalmology, 2013, 156, 23-28.e2.	3.3	123
760	<scp>KH902</scp> suppresses high glucoseâ€induced migration andÂsprouting of human retinal endothelial cells by blocking <scp>VEGF</scp> and <scp>PlGF</scp>. Diabetes, Obesity and Metabolism, 2013, 15, 224-233.	4.4	39
761	Age-Related Macular Degeneration. Pharmacotherapy, 2013, 33, 838-855.	2.6	95
762	Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4â€ƒweeks, 6â€ƒweeks and 8â€ƒweeks. Acta Ophthalmologica, 2013, 91, e456-e461.	1.1	23
763	Ranibizumab Is a Potential Prophylaxis for Proliferative Vitreoretinopathy, a Nonangiogenic Blinding Disease. American Journal of Pathology, 2013, 182, 1659-1670.	3.8	45
764	Combination Therapies for the Treatment of AMD. , 2013, , 247-261.		1
765	Intravitreal aflibercept for neovascular age-related macular degeneration. Immunotherapy, 2013, 5, 121-130.	2.0	9
766	The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation. Vojnosanitetski Pregled, 2013, 70, 660-663.	0.2	2
767	Primary effects of intravitreal bevacizumab inpatients with diabetic macular edema. Pakistan Journal of Medical Sciences, 2013, 29, 1018-22.	0.6	5
768	Anti-vascular endothelial growth factor in age-related macular degeneration: Puzzle or a silent beginning!. Indian Journal of Ophthalmology, 2013, 61, 475.	1.1	3
769	Exploratory Analysis of the Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial. JAMA Ophthalmology, 2013, 131, 1033.	2.5	99
770	Progression of Lesion Size in Untreated Eyes With Exudative Age-Related Macular Degeneration. JAMA Ophthalmology, 2013, 131, 335.	2.5	31
771	Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model. International Journal of Molecular Sciences, 2013, 14, 8291-8305.	4.1	8
772	Efficacy of Intravitreal Bevacizumab With Panretinal Photocoagulation Followed by Ahmed Valve Implantation in Neovascular Glaucoma. Journal of Glaucoma, 2013, 22, 768-772.	1.6	44
773	Recurrence of Corneal Neovascularization Associated With Lipid Deposition After Subconjunctival Injection of Bevacizumab. Cornea, 2013, 32, 1446-1453.	1.7	13
774	ALTERATIONS OF VASCULAR PIGMENT EPITHELIUM DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION DURING UPLOAD WITH INTRAVITREAL RANIBIZUMAB. Retina, 2013, 33, 1843-1849.	1.7	13
775	Influence of Preoperative Intravitreal Bevacizumab on Visual Function in Eyes with Proliferative Diabetic Retinopathy. Ophthalmic Research, 2013, 49, 30-36.	1.9	11
776	Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. Middle East African Journal of Ophthalmology, 2013, 20, 51.	0.3	16

#	Article	IF	Citations
777	The Efficacy of Intravitreal Bevacizumab for Acute Central Serous Chorioretinopathy. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 10-13.	1.4	23
778	Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6115-6120.	7.1	57
780	MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS. Retina, 2013, 33, 920-927.	1.7	42
781	INCIDENCE OF ACUTE ENDOPHTHALMITIS AFTER INTRAVITREAL BEVACIZUMAB INJECTION IN A SINGLE CLINICAL CENTER. Retina, 2013, 33, 971-974.	1.7	37
782	INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF DIABETIC OCULAR NEOVASCULARIZATION. Retina, 2013, 33, 748-755.	1.7	15
783	CORRELATION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS WITH VISUAL ACUITY IN EYES WITH SUBFOVEAL SCARRING AFTER TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 1249-1257.	1.7	11
784	Vascular Endothelial Growth Factor Inhibitors for Treatment of Corneal Neovascularization. Cornea, 2013, 32, 435-444.	1.7	40
785	Topical Ranibizumab as a Treatment of Corneal Neovascularization. Cornea, 2013, 32, 992-997.	1.7	76
786	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clinical Ophthalmology, 2013, 7, 1987.	1.8	28
787	The Results of Switching between 2 Anti-VEGF Drugs, Bevacizumab and Ranibizumab, in the Treatment of Neovascular Age-related Macular Degeneration. European Journal of Ophthalmology, 2013, 23, 553-557.	1.3	23
788	Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography. Korean Journal of Ophthalmology: KJO, 2013, 27, 425.	1.1	19
789	Clinical Manifestation of Retinal Pigment Epithelial Tear after Treatment of Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2013, 54, 1540.	0.2	3
790	Prevalence of Neutralizing Factors Against Adeno-Associated Virus Types 2 in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Current Gene Therapy, 2013, 13, 182-188.	2.0	7
791	Combined Scraping, Coagulation, and Subconjunctival Bevacizumab in Descemet Stripping Automated Endothelial Keratoplasty for Bullous Keratopathy. European Journal of Ophthalmology, 2013, 23, 309-315.	1.3	1
792	Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2013, 2013, 1-9.	1.3	17
793	Anti VEGF Agents for Age Related Macular Degeneration. , 2013, , .		0
794	Intravitreal Bevacizumab Injection for Serous Retinal Detachment Associated with Leber's Idiopathic Stellate Neuroretinitis. Journal of Korean Ophthalmological Society, 2014, 55, 1562.	0.2	1
795	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab Injection. Journal of Korean Ophthalmological Society, 2014, 55, 780.	0.2	0

#	Article	IF	Citations
796	Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration. Journal of Ophthalmology, 2014, 2014, 1-6.	1.3	38
797	Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clinical Ophthalmology, 2014, 8, 1383.	1.8	16
798	Metamorphopsia and letter recognition. Journal of Vision, 2014, 14, 1-1.	0.3	16
799	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration. Clinical Ophthalmology, 2014, 8, 981.	1.8	1
800	Vision Rehabilitation in Patients with Age-related Macular Degeneration. Rehabilitation Process and Outcome, 2014, 3, RPO.S12364.	1.6	2
801	The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema. Journal of Ophthalmology, 2014, 2014, 1-6.	1.3	16
802	Ranibizumab Treatment for Choroidal Neovascularization Secondary to Causes Other than Age-Related Macular Degeneration with Good Baseline Visual Acuity. Seminars in Ophthalmology, 2014, 29, 108-113.	1.6	12
803	Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye, 2014, 28, 576-580.	2.1	30
804	Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology, 2014, 132, 915.	2.5	87
805	Cost-Related Motivations for Conducting Research. JAMA - Journal of the American Medical Association, 2014, 311, 1491.	7.4	5
806	Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison. Ophthalmologica, 2014, 232, 149-155.	1.9	8
807	Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment. BMC Research Notes, 2014, 7, 617.	1.4	8
808	INTRAVITREAL BEVACIZUMAB FOR POSTOPERATIVE RECURRENT VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2014, 34, 1177-1181.	1.7	17
809	INTRAVITREAL ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION IN OCULAR HISTOPLASMOSIS. Retinal Cases and Brief Reports, 2014, 8, 24-29.	0.6	11
810	Growth of Geographic Atrophy on Fundus Autofluorescence and Polymorphisms ofCFH,CFB,C3,FHR1-3, andARMS2in Age-Related Macular Degeneration. JAMA Ophthalmology, 2014, 132, 528.	2.5	34
811	A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 104-115.	4.3	47
812	Protective effect of a laser-induced sub-lethal temperature rise on RPE cells from oxidative stress. Experimental Eye Research, 2014, 124, 37-47.	2.6	37
813	Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 889-897.	1.9	15

#	Article	IF	Citations
814	Pathologic Myopia. , 2014, , .		41
815	The effect of intravitreal bevacizumab injection before Ahmed valve implantation in patients with neovascular glaucoma. International Ophthalmology, 2014, 34, 793-799.	1.4	31
816	In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications. International Journal of Pharmaceutics, 2014, 470, 151-157.	5.2	93
817	Anti-vascular endothelial growth factor for diabetic macular oedema. , 2014, , CD007419.		113
818	Effects of ranibizumab on the extracellular matrix production by human Tenon's fibroblast. Experimental Eye Research, 2014, 127, 236-242.	2.6	8
819	Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation. British Journal of Ophthalmology, 2014, 98, 454-458.	3.9	29
820	Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care. British Journal of Ophthalmology, 2014, 98, 1333-1337.	3.9	12
821	The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 158, 769-779.e2.	3.3	167
822	Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report. Journal of Medical Case Reports, 2014, 8, 48.	0.8	4
823	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology, 2014, 98, 1144-1167.	3.9	463
824	Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Survey of Ophthalmology, 2014, 59, 134-165.	4.0	93
825	Intravitreal Anti-Vascular Endothelial Growth Factor for Submacular Hemorrhage from Choroidal Neovascularization. Ophthalmology, 2014, 121, 926-935.	5.2	69
826	Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2014, 121, 150-161.	5.2	483
827	Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen. Taiwan Journal of Ophthalmology, 2014, 4, 3-8.	0.7	4
828	Progress on retinal image analysis for age related macular degeneration. Progress in Retinal and Eye Research, 2014, 38, 20-42.	15.5	132
829	The Effect of Bevacizumab on Wound Healing Modulation in an Experimental Trabeculectomy Model. Current Eye Research, 2014, 39, 451-459.	1.5	21
830	Retinal and Choroidal Thickness Changes after Single Anti-VEGF Injection in Neovascular Age-related Macular Degeneration: Ranibizumab vs Bevacizumab. European Journal of Ophthalmology, 2014, 24, 904-910.	1.3	20
831	The Role of Intraoperative Bevacizumab for Prevention of Postoperative Vitreous Hemorrhage in Diabetic Vitreous Hemorrhage. European Journal of Ophthalmology, 2014, 24, 88-93.	1.3	7

#	Article	IF	Citations
832	Antiâ€<scp>VEGF</scp>s hinder bone healing and implant osseointegration in rat tibiae. Journal of Clinical Periodontology, 2015, 42, 688-696.	4.9	36
833	DIFFERENTIAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-A ISOFORMS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 764-772.	1.7	16
834	VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1750-1756.	1.7	21
835	Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean Journal of Ophthalmology: KJO, 2015, 29, 226.	1.1	25
836	Corneal Neovascularization: A Translational Perspective. Journal of Clinical & Experimental Ophthalmology, 2015, 06, .	0.1	0
837	Bevacizumab and Aflibercept Activate Platelets via FcÎ³RIIa. , 2015, 56, 8075.		17
838	Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. Korean Journal of Ophthalmology: KJO, 2015, 29, 315.	1.1	14
839	Vascular Endothelial Growth Factor: An Overview Across Multiple Disease Conditions. American Journal of Pharmacology and Toxicology, 2015, 10, 1-12.	0.7	3
840	Correlation Between Hyperreflective Foci and Clinical Outcomes in Neovascular Age-Related Macular Degeneration After Switching to Aflibercept. , 2015, 56, 6448.		34
841	Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. , 2015, 56, 5040.		46
842	Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab. BioMed Research International, 2015, 2015, 1-6.	1.9	7
843	Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child. Eye, 2015, 29, 569-573.	2.1	5
845	Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 287-294.	1.9	28
846	Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing ahmed glaucoma valve implantation: 2â€year followâ€up. Acta Ophthalmologica, 2015, 93, e1-6.	1.1	37
847	The Effect of Intravitreal Bevacizumab as a Pretreatment of Vitrectomy for Diabetic Vitreous Hemorrhage on Recurrent Hemorrhage. Seminars in Ophthalmology, 2015, 30, 177-180.	1.6	10
848	Nanoparticles for the treatment of ocular neovascularizations. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 294-306.	4.3	31
849	Routine versus As-Needed Bevacizumab withÂ12-Weekly Assessment Intervals forÂNeovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1348-1355.	5.2	11
850	The Relationship between Medicare Payment and Service Volume for Retina Procedures from 2005 through 2009. Ophthalmology, 2015, 122, 1609-1614.	5.2	4

#	Article	IF	Citations
851	Predictors of visual and anatomical outcomes for neovascular age-related macular degeneration treated with bevacizumab. Biomedical Reports, 2015, 3, 503-508.	2.0	5
852	Prospective Comparison of Low-Fluence Photodynamic Therapy Combined with Intravitreal Bevacizumab versus Bevacizumab Monotherapy for Choroidal Neovascularization in Age-Related Macular Degeneration. Seminars in Ophthalmology, 2015, 30, 112-117.	1.6	10
853	Role of Subconjunctival Bevacizumab as an Adjuvant to Primary Trabeculectomy. Journal of Glaucoma, 2015, 24, 1-8.	1.6	44
854	Combination Therapy with Intravitreal Bevacizumab and Macular Grid and Scatter Laser Photocoagulation in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 179-185.	1.4	7
855	Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2015, 122, 809-816.	5.2	186
856	Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology, 2015, 122, 2523-2531.e1.	5.2	84
857	Encapsulated cells for long-term secretion of soluble VEGF receptor 1: Material optimization and simulation of ocular drug response. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 387-397.	4.3	19
858	Bevacizumab Revisited: Its Use in Different Mouse Models of Ocular Pathologies. Current Eye Research, 2015, 40, 611-621.	1.5	24
859	Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Secondary to Toxoplasmic Retinochoroiditis: A Case Series. Seminars in Ophthalmology, 2015, 30, 181-187.	1.6	11
860	Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis. British Journal of Ophthalmology, 2015, 99, 593-598.	3.9	23
861	Is Spectral-Domain Optical Coherence Tomography Always Able to Detect the Anti-Vascular Endothelial Growth Factor Action on Neovascular Membrane. Case Reports in Ophthalmology, 2016, 7, 309-314.	0.7	0
862	High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2016, 30, 265.	1.1	9
863	Intravitreal bevacizumab for treatment of central serous chorioretinopathy. Journal of Ophthalmic and Vision Research, 2016, 11, 61.	1.0	16
864	Automated Retinal Layer Segmentation Using Spectral Domain Optical Coherence Tomography: Evaluation of Inter-Session Repeatability and Agreement between Devices. PLoS ONE, 2016, 11, e0162001.	2.5	49
865	Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis, 2016, 19, 389-406.	7.2	29
866	Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review. Ophthalmic Research, 2016, 55, 185-193.	1.9	49
867	GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration. Scientific Reports, 2016, 6, 37924.	3.3	23
868	Assessment of bevacizumab quality and stability in repackaged syringes for clinical use. European Journal of Hospital Pharmacy, 2016, 23, 343-347.	1.1	2

#	Article	IF	Citations
869	Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: TheÂDunedin Hospital experience. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 756-763.	1.8	9
870	Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1731-1736.	1.9	12
871	Five-Year Outcomes with Antiâ€"Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 1751-1761.	5.2	541
872	Importance of Lid Hygiene Before Ocular Surgery: Qualitative and Quantitative Analysis of Eyelid and Conjunctiva Microbiota. Eye and Contact Lens, 2016, 42, 366-370.	1.6	30
873	Physician-Industry Interactions and Antiâ€"Vascular Endothelial Growth Factor Use Among US Ophthalmologists. JAMA Ophthalmology, 2016, 134, 897.	2.5	58
874	Unilateral metamorphopsia in a 73 year old woman. BMJ, The, 2016, 354, i3720.	6.0	0
875	Optical Coherence Tomography Angiography of Mixed Neovascularizations in Age-Related Macular Degeneration. Developments in Ophthalmology, 2016, 56, 62-70.	0.1	12
876	Principles of Ocular Pharmacology. Handbook of Experimental Pharmacology, 2016, 242, 3-30.	1.8	0
877	Anti-angiogenic Therapy for Retinal Disease. Handbook of Experimental Pharmacology, 2016, 242, 271-307.	1.8	38
878	Growth factor restriction impedes progression of wound healing following cataract surgery: identification of VEGF as a putative therapeutic target. Scientific Reports, 2016, 6, 24453.	3.3	16
879	Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Eye, 2016, 30, 1077-1083.	2.1	13
880	Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series. International Journal of Retina and Vitreous, 2016, 2, 2.	1.9	14
881	Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye, 2016, 30, 805-811.	2.1	29
882	The effect of intravitreal injection of vehicle solutions on form deprivation myopia in tree shrews. Experimental Eye Research, 2016, 145, 289-296.	2.6	21
883	Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration. Tissue Engineering - Part B: Reviews, 2016, 22, 341-357.	4.8	8
884	Treatment for neovascular age related macular degeneration: The state of the art. European Journal of Pharmacology, 2016, 787, 78-83.	3.5	21
885	Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. Journal of Controlled Release, 2017, 258, 208-217.	9.9	35
886	Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2017, 101, 1003-1010.	3.9	9

#	Article	IF	Citations
887	Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. Advanced Healthcare Materials, 2017, 6, 1700733.	7.6	12
888	Prevalence of Age-Related Macular Degeneration in Australia. JAMA Ophthalmology, 2017, 135, 1242.	2.5	34
889	DÃ©veloppement galÃ©nique et analytique dâ€™un collyre au bÃ©vacizumab Ã 5Âmg/mLÂ: Ã©tude de stabilitÃ©. Pharmacien Hospitalier Et Clinicien, 2017, 52, 325-331.	0.3	0
890	Comparison of Topical Low-Molecular-Weight Heparinâ€“Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization. Cornea, 2017, 36, 497-501.	1.7	3
891	Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States. American Journal of Ophthalmology, 2017, 184, 157-166.	3.3	15
892	INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 1337-1344.	1.7	13
893	Retinal vascular injuries and intravitreal human embryonic stem cellâ€derived haemangioblasts. Acta Ophthalmologica, 2017, 95, e468-e476.	1.1	2
894	Human bone marrow mesenchymal stem cells for retinal vascular injury. Acta Ophthalmologica, 2017, 95, e453-e461.	1.1	21
895	Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 475-484.	1.9	12
896	New Treatment Modalities for Neovascular Age-Related Macular Degeneration. Asia-Pacific Journal of Ophthalmology, 2017, 6, 514-519.	2.5	23
897	Comparison of Choroidal Thickness Change between Ranibizumab and Aflibercept in Age-related Macular Degeneration: Six Month Results. Journal of Korean Ophthalmological Society, 2017, 58, 296.	0.2	1
898	Simultaneous multimodal ophthalmic imaging using swept-source spectrally encoded scanning laser ophthalmoscopy and optical coherence tomography. Biomedical Optics Express, 2017, 8, 193.	2.9	23
899	Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides. , 2017, 58, 2578.		70
900	The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 859-869.	0.7	2
901	Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes. Journal of Ophthalmology, 2017, 2017, 1-5.	1.3	5
902	Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration. PLoS ONE, 2017, 12, e0185070.	2.5	5
903	Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. BMC Ophthalmology, 2017, 17, 189.	1.4	26
904	Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 651-663.	1.9	24

#	Article	IF	Citations
905	Mortality after a cerebrovascular event in ageâ€related macular degeneration patients treated with bevacizumab ocular injections. Acta Ophthalmologica, 2018, 96, e732-e739.	1.1	18
906	Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges. Advanced Drug Delivery Reviews, 2018, 126, 145-161.	13.7	34
907	Evolution of Intravitreal Therapy for Retinal Diseasesâ€"From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture. American Journal of Ophthalmology, 2018, 191, xli-lviii.	3.3	32
908	Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 511-518.	1.9	20
909	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Progress in Retinal and Eye Research, 2018, 65, 127-146.	15.5	205
910	The association between myocardial infarction and intravitreal bevacizumab injection. Medicine (United States), 2018, 97, e0198.	1.0	8
911	The suprachoroidal space as a route of administration to the posterior segment of the eye. Advanced Drug Delivery Reviews, 2018, 126, 58-66.	13.7	77
912	RESIDUAL CHOROIDAL VESSELS IN ATROPHY CAN MASQUERADE AS CHOROIDAL NEOVASCULARIZATION ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina, 2018, 38, 1289-1300.	1.7	21
913	Estimating Public and Patient Savings From Basic Researchâ€"A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy. American Journal of Ophthalmology, 2018, 185, 115-122.	3.3	35
914	Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research, 2018, 63, 20-68.	15.5	422
915	Imaging retinal melanin: a review of current technologies. Journal of Biological Engineering, 2018, 12, 29.	4.7	50
916	Negative regulators of angiogenesis, ocular vascular homeostasis, and pathogenesis and treatment of exudative AMD. Journal of Ophthalmic and Vision Research, 2018, 13, 470.	1.0	21
917	Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. Biomedicine and Pharmacotherapy, 2018, 107, 1056-1063.	5.6	49
918	Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS ONE, 2018, 13, e0202436.	2.5	11
919	Development and validation of a novel semi-homogenous clinical assay for quantitation of Ranibizumab in human serum. Journal of Immunological Methods, 2018, 461, 44-52.	1.4	11
920	Would intravitreal bevacizumab injection increase risk of cerebral infarction?. European Journal of Neurology, 2018, 25, 1177-1181.	3.3	0
921	Understanding Variation in Response to Antiâ€"Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2018, 136, 884.	2.5	1
922	Pars plana vitrectomy in vitreous hemorrhage with or without Intravitreal Bevacizumab a comparative overview. Pakistan Journal of Medical Sciences, 2018, 34, 221-225.	0.6	9

#	Article	IF	Citations
923	Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. BioMed Research International, 2018, 2018, 1-9.	1.9	3
924	Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is Associated With Therapy Response in Wet Age-Related Macular Degeneration. , 2018, 59, 1944.		20
925	Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis. Ophthalmology Retina, 2018, 2, 1087-1096.	2.4	11
926	Time trends, disease patterns and gender imbalance in the top 100 most cited articles in ophthalmology. British Journal of Ophthalmology, 2019, 103, 18-25.	3.9	21
927	Clinical Changes after Switching from Ranibizumab/Aflibercept to Bevacizumab in Exudative Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2019, 60, 40.	0.2	2
928	Intravitreal Ziv-Aflibercept: A Comprehensive Review. Seminars in Ophthalmology, 2019, 34, 420-435.	1.6	12
929	Preclinical Evaluation of UDCA-Containing Oral Formulation in Mice for the Treatment of Wet Age-Related Macular Degeneration. Pharmaceutics, 2019, 11, 561.	4.5	9
930	Association of Intravitreal Antiâ€"Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration. JAMA Ophthalmology, 2019, 137, 483.	2.5	41
931	Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration. Arquivos Brasileiros De Oftalmologia, 2019, 82, 225-232.	0.5	4
932	Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid. BMC Ophthalmology, 2019, 19, 103.	1.4	6
933	Repeated retinal photocoagulation in monkeys for the optimization of a laser-induced choroidal neovascularization model. Experimental Eye Research, 2019, 184, 1-7.	2.6	5
934	Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study. Ophthalmologica, 2019, 241, 211-219.	1.9	12
935	In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor. Research in Veterinary Science, 2019, 124, 233-238.	1.9	9
936	Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases. International Journal of Pharmaceutics, 2019, 563, 228-236.	5.2	31
937	Serum vascular endothelial growth factor changes and safety after topical antiâ€human VEGF antibody bevacizumab in healthy dogs. Veterinary Ophthalmology, 2019, 22, 600-606.	1.0	3
938	The use of real-world evidence for evaluating antiâ€"vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Survey of Ophthalmology, 2019, 64, 707-719.	4.0	25
939	Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles. Nature Communications, 2019, 10, 804.	12.8	67
940	Synergy of Ginkgetin and Resveratrol in Suppressing VEGF-Induced Angiogenesis: A Therapy in Treating Colorectal Cancer. Cancers, 2019, 11, 1828.	3.7	51

#	Article	IF	Citations
941	Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice. Frontiers in Aging Neuroscience, 2019, 11, 309.	3.4	10
942	Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH. Journal of Biological Chemistry, 2019, 294, 17603-17611.	3.4	2
943	Upcoming Therapies for Age-related Macular Degeneration. International Ophthalmology Clinics, 2019, 59, 155-171.	0.7	0
944	Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch. International Ophthalmology, 2019, 39, 2023-2031.	1.4	6
945	Retinal Degeneration. Methods in Molecular Biology, 2019, , .	0.9	5
946	Nanoparticles Targeting Retinal and Choroidal Capillaries In Vivo. Methods in Molecular Biology, 2019, 1834, 391-404.	0.9	3
947	Nanoengineered biomaterials for retinal repair. , 2019, , 215-264.		5
948	EFFECT OF INTRAOCULAR PRESSUREâ€“LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Retina, 2019, 39, 636-647.	1.7	5
949	Age-Related Macular Degeneration Preferred Practice PatternÂ®. Ophthalmology, 2020, 127, P1-P65.	5.2	167
950	Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. Ophthalmology Retina, 2020, 4, 403-414.	2.4	25
951	Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome. Journal of Glaucoma, 2020, 29, 981-988.	1.6	3
952	A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression. Frontiers in Pharmacology, 2020, 11, 1043.	3.5	24
953	Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2020, 14, 117954842092928.	0.9	2
954	Intravitreal hydrogels for sustained release of therapeutic proteins. Journal of Controlled Release, 2020, 326, 419-441.	9.9	76
955	VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Scientific Reports, 2020, 10, 12409.	3.3	48
956	Trends in Real-World Neovascular AMD Treatment Outcomes in the UK . Clinical Ophthalmology, 2020, Volume 14, 3331-3342.	1.8	29
957	Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation. International Journal of Pharmaceutics, 2020, 590, 119895.	5.2	12
958	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences, 2020, 21, 8242.	4.1	82

#	Article	IF	Citations
959	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. BMC Ophthalmology, 2020, 20, 21.	1.4	1
960	Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies. Drug Delivery and Translational Research, 2020, 10, 1191-1202.	5.8	6
961	The influence of dead spaces and the designs of injectors on the amount of drug dose in intra-vitreal injection. European Journal of Ophthalmology, 2021, 31, 592-599.	1.3	4
962	Choroidal Neovascular Membrane. , 2021, , 367-382.		0
963	Wavelet-Based Robust Estimation of Hurst Exponent with Application in Visual Impairment Classification. Journal of Data Science, 2020, 18, 581-605.	0.9	3
964	Choroidal Neovascularization. , 2021, , 271-293.		0
965	The Relationship Between Corneal Biomechanics and Intraocular Pressure Dynamics in Patients Undergoing Intravitreal Injection. Journal of Glaucoma, 2021, 30, 451-458.	1.6	2
966	Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry. Eye, 2021, , .	2.1	4
967	A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability. Pharmaceutics, 2021, 13, 560.	4.5	10
968	Ion-Complex Microcrystal Formulation Provides Sustained Delivery of a Multimodal Kinase Inhibitor from the Subconjunctival Space for Protection of Retinal Ganglion Cells. Pharmaceutics, 2021, 13, 647.	4.5	10
969	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. Expert Review of Ophthalmology, 2021, 16, 267-286.	0.6	0
970	Effect of Bevacizumab on Recurrent Laryngeal Papilloma. Koutou (the LARYNX JAPAN), 2021, 33, 50-53.	0.1	0
971	The 100 most-cited papers on age-related macular degeneration: a bibliographic perspective. BMJ Open Ophthalmology, 2021, 6, e000823.	1.6	4
972	Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. Pharmaceutics, 2021, 13, 1102.	4.5	8
974	Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration. Photodiagnosis and Photodynamic Therapy, 2021, 35, 102383.	2.6	3
975	Cambio de grosor macular central con la administraciÃ³n de Bevacizumab IntravÃtreo. Revista De La Facultad De Medicina, 2017, 1, .	0.0	0
976	Ocular Neovascularization. , 2008, , 517-531.		3
977	Protein Drug Delivery and Formulation Development. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 409-448.	0.6	4

#	Article	IF	Citations
978	Economic Considerations in Medical Biotechnology. , 2013, , 237-245.		1
980	Principles and Applications of Modern Optical Coherence Tomography. , 2009, , 67-83.		1
981	Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmology Clinics of North America, 2006, 19, 335-44.	1.8	76
982	Ranibizumab: Phase III clinical trial results. Ophthalmology Clinics of North America, 2006, 19, 361-72.	1.8	229
983	Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmologica, 2007, 85, 563-565.	0.3	39
984	Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmologica, 2007, 85, 526-534.	0.3	47
985	Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmologica, 2007, 85, 486-494.	0.3	72
986	Age-related Macular Degeneration: Genetic and Environmental Factors of Disease. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2010, 10, 271-281.	3.4	113
987	Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. British Journal of Ophthalmology, 2007, 91, 166-173.	3.9	33
988	Selective Inhibition of Retinal Angiogenesis by Targeting PI3 Kinase. PLoS ONE, 2009, 4, e7867.	2.5	65
989	Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect In Vivo. PLoS ONE, 2013, 8, e70544.	2.5	82
990	Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization. PLoS ONE, 2014, 9, e94205.	2.5	37
991	Preparation and in vitro characterization of monoclonal antibody ranibizumab conjugated magnetic nanoparticles for ocular drug delivery. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	7
992	Ranibizumab in neovascular age-related macular degeneration. Clinical Interventions in Aging, 2006, 1, 451-466.	2.9	15
993	Efficacy of intravitreal bevacizumab (AvastinTM) for short-term treatment of diabetic macular edema. Journal of Medical Investigation, 2009, 56, 111-115.	0.5	8
994	Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Current Drug Metabolism, 2015, 16, 572-584.	1.2	41
995	Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions. Current Pharmaceutical Biotechnology, 2014, 15, 113-119.	1.6	18
996	Anti-VEGF Treatment in Corneal Diseases. Current Drug Targets, 2020, 21, 1159-1180.	2.1	24

#	Article	IF	Citations
997	Reversal of Retinal Vascular Changes Associated with Ocular Neovascularization by Small Molecules: Progress toward Identifying Molecular Targets for Therapeutic Intervention. The Open Diabetes Journal, 2011, 4, 75-95.	0.4	3
998	Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. Romanian Journal of Ophthalmology, 2017, 61, 207-211.	0.5	6
999	The Treatment of Wet Age-Related Macular Degeneration. Deutsches Ärzteblatt International, 2009, 106, 312-7.	0.9	19
1000	A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technology Assessment, 2015, 19, 1-298.	2.8	62
1001	Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular Degeneration. International Journal of Molecular Sciences, 2020, 21, 9752.	4.1	10
1002	Intravitreal Bevacizumab Following Laser Therapy for Severe Retinopathy of Prematurity. Journal of Pediatric Ophthalmology and Strabismus, 2010, 47 Online, e1-4.	0.7	4
1003	Safety and Efficacy of Intravitreal Bevacizumab Followed by Pegaptanib Maintenance as a Treatment Regimen for Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2006, 37, 446-454.	0.7	31
1004	Intravitreal Bevacizumab for Macular Edema From Idiopathic Juxtafoveal Retinal Telangiectasis. Ophthalmic Surgery Lasers and Imaging Retina, 2007, 38, 164-166.	0.7	30
1005	Extrafoveal Choroidal Neovascularization Secondary to Wet Age-Related Macular Degeneration Treated With Intravitreal Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2007, 38, 226-228.	0.7	9
1006	Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity. Ophthalmic Surgery Lasers and Imaging Retina, 2007, 38, 233-237.	0.7	132
1007	Treatment of Neovascular Age-Related Macular Degeneration with Pegaptanib and Boosting with Bevacizumab or Ranibizumab as Needed. Ophthalmic Surgery Lasers and Imaging Retina, 2008, 39, 294-298.	0.7	7
1008	Vitrectomy After Anti-Vegf Therapy for Epiretinal Membranes Coincident with Age-Related Subfoveal Choroidal Neovascularization. Ophthalmic Surgery Lasers and Imaging Retina, 2008, 39, 455-459.	0.7	2
1009	Acute Visual Acuity Loss Following Intravitreal Bevacizumab for Diabetic Macular Edema. Ophthalmic Surgery Lasers and Imaging Retina, 2009, 40, 68-70.	0.7	37
1010	Prophylactic Treatment of Age-Related Macular Degeneration Report Number 2: 810-Nanometer Laser to Eyes With Drusen: Bilaterally Eligible Patients. Ophthalmic Surgery Lasers and Imaging Retina, 2009, 40, 530-538.	0.7	26
1011	Clinical Course of Choroidal Neovascularization Secondary to Angioid Streaks Treated with Intravitreal Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 546-549.	0.7	13
1012	Uveitis Following Intravitreal Bevacizumab: A Non-Infectious Cluster. Ophthalmic Surgery Lasers and Imaging Retina, 2011, 42, 292-296.	0.7	35
1013	Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2013, 44, 25-27.	0.7	18
1014	Association Between Systemic Anticoagulation and Rate of Intraocular Hemorrhage Following Intravitreal Anti-VEGF Therapy for Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2013, 44, 455-459.	0.7	11

#	Article	IF	Citations
1015	Ocular Hypertension and Intraocular Pressure Asymmetry After Intravitreal Injection of Antiâ€“Vascular Endothelial Growth Factor Agents. Ophthalmic Surgery Lasers and Imaging Retina, 2013, 44, 460-464.	0.7	34
1016	Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration. International Journal of Ophthalmology, 2011, 4, 85-8.	1.1	9
1017	Role of ranibizumab in management of macular degeneration. Indian Journal of Ophthalmology, 2007, 55, 421.	1.1	13
1018	A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian Journal of Ophthalmology, 2007, 55, 437.	1.1	29
1019	Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian Journal of Ophthalmology, 2007, 55, 457.	1.1	14
1020	Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye. Indian Journal of Ophthalmology, 2007, 55, 460.	1.1	15
1021	Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian Journal of Ophthalmology, 2007, 55, 488.	1.1	8
1022	Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats. Journal of Research in Medical Sciences, 2017, 22, 16.	0.9	2
1023	Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration. Journal of Ophthalmic and Vision Research, 2014, 9, 449.	1.0	11
1024	Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization. Journal of Ophthalmic and Vision Research, 2015, 10, 484.	1.0	10
1025	A novel multifunctional, intravitreal injection assistant: evaluation and comparison with conventional technique. Journal of the Egyptian Ophthalmological Society, 2016, 109, 122.	0.1	1
1026	Effect of Intravitreal Injection of Bevacizumab on Acute Central Serous Chorioretinopathy Patients who Visited Feiz Hospital during 2014â€“2015 Period. Advanced Biomedical Research, 2017, 6, 125.	0.5	2
1027	Efficacy of intravitreal bevacizumab for the treatment of Zone I Type 1 retinopathy of prematurity. Journal of Ophthalmic and Vision Research, 2018, 13, 29.	1.0	8
1028	Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study. Taiwan Journal of Ophthalmology, 2019, 9, 249.	0.7	4
1029	Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia. TÃ¼rk Oftalmoloji Dergisi, 2017, 47, 144-148.	0.9	6
1031	Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration. ISRN Ophthalmology, 2011, 2011, 1-4.	1.7	2
1032	Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: Rapid distribution throughout the posterior segment. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 200-210.	4.3	5
1033	Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan. Pharmaceutics, 2021, 13, 1685.	4.5	25

#	Article	IF	Citations
1034	Altersbedingte Makuladegeneration. Pharma-Kritik (discontinued), 2006, 27, .	0.0	0
1036	Laser Photocoagulation for Choroidal Neovascularization. , 2007, , 221-224.		0
1038	Intraviteal Bevacizumab (AvastinÂ®) Injection for the Treatment of Early-Stage Neovascular Glaucoma. Journal of Korean Ophthalmological Society, 2008, 49, 696.	0.2	4
1040	Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents. Indian Journal of Ophthalmology, 2009, 57, 146.	1.1	0
1041	Effectiveness of Preoperative Intravitreal Bevacizumab Injections in Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 1221.	0.2	1
1046	Bevacizumab (Avastin) inhibits corneal neovascularization in rabbits. Academic Journal of Second Military Medical University, 2009, 29, 907-912.	0.0	0
1047	Intravitreal Bevacizumab for Macular Edema from Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis. Ophthalmic Surgery, Lasers and Imaging, 2010, , 1-3.	0.5	1
1048	Combination Therapy with Ocular Photodynamic Therapy for Age-Related Macular Degeneration. , 2011, , 99-118.		0
1049	Anti-VEGF-Therapie aus kardiologischer Sicht. , 2011, , 131-142.		0
1050	Kombinationstherapien zur Behandlung der AMD. , 2011, , 253-268.		0
1051	VEGF Inhibitor Induced Oxidative Stress in Retinal Ganglion Cells. , 2012, , 585-593.		0
1053	Combination Treatment Strategies in Neovascular AMD. , 2012, , 501-515.		0
1054	Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab. Ophthalmic Surgery, Lasers and Imaging, 0, , .	0.5	0
1055	Choroidal Neovascular Membrane. , 2013, , 255-267.		0
1056	The Frequency of the Nonresponsiveness to Intravitreal Injection of the Anti-Vascular Endothelial Growth Factor Agent in Neovascular Age Related Macular Degeneration. International Journal of Ophthalmic Pathology, 2013, 02, .	0.1	1
1057	Neovascular Age-Related Macular Degeneration: Rationale for Current Treatment Guidelines. Essentials in Ophthalmology, 2013, , 107-125.	0.1	0
1058	Subconjunctival Bevacizumab Injection in Treatment of Recurrent Pterygium. Journal of Clinical & Experimental Ophthalmology, 2013, 04, .	0.1	3
1059	Choroidal Neovascularization. , 2014, , 211-230.		0

#	Article	IF	Citations
1060	Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab. BioMed Research International, 2014, 2014, 1-6.	1.9	2,069
1061	Aqueous Interleukin-6 (IL-6) Level Is a Marker for Treatment Resistance to Bevacizumab in Age-Related Macular Degeneration â€"Aqueous Cytokines after Bevacizumab. Open Journal of Ophthalmology, 2014, 04, 24-30.	0.3	1
1062	A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents. Delhi Journal of Ophthalmology, 2014, 24, 241-244.	0.1	0
1063	The Study on the Korean and Western Medical Literatures for Age-Related Macular Degeneration. The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology, 2015, 28, 66-75.	0.0	0
1064	Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digital Journal of Ophthalmology: DJO, 2015, 21, 29-34.	0.6	7
1065	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. International Journal of Particle Therapy, 2016, 2, 555-569.	1.8	0
1066	6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome. International Journal of Ophthalmology, 2016, 9, 551-5.	1.1	1
1067	Efficacy of Anti-VEGF and Subtenon Injection of Triamcinolone Acetonide for Choroidal Neovascularization Associated with Multifocal Choroiditis. Open Journal of Ophthalmology, 2017, 07, 117-123.	0.3	0
1068	Post-traumatic Uveitis and Post-operative Inflammation. , 2017, , 275-284.		1
1069	The non-Responsiveness to Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Neovascularage-Related Macular Degeneration. Advances in Ophthalmology & Visual System, 2017, 6, .	0.2	0
1070	SAFETY AND EFFICACY OF PREOP INTRAVITREAL TRIAMCINOLONE PLUS BEVACIZUMAB COMBINATION AND BEVACIZUMAB ALONE IN VITREOUS SURGERY FOR NON-RESOLVING VITREOUS HAEMORRHAGE IN PROLIFERATIVE DIABETIC RETINOPATHY (PDR). Journal of Evidence Based Medicine and Healthcare, 2018, 4, 218-221.	0.0	0
1071	Traitement de la dÃ©gÃ©nÃ©rescence maculaire liÃ©e Ã l'Ã¢ge. , 2018, , 1025-1035.e1.		0
1072	Characterization of Patients With Geographic Atrophy in Routine Clinical Practice. Ophthalmic Surgery Lasers and Imaging Retina, 2019, 50, 93-98.	0.7	0
1073	Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the antiâ€'VEGF era in Romania. Experimental and Therapeutic Medicine, 2019, 18, 4993-5000.	1.8	15
1074	Diyabetik Makula Ã–deminde Ä°ntravitreal Bevacizumab Tedavisinin Santral Makula KalÄ±nlÄ±ÄŸÄ± Ve Santral Retina DuyarlÄ±lÄ±ÄŸÄ± Ãœzerine Etkisi. Ege TÄ±p Bilimleri Dergisi, 2020, 3, 59-66.	0.3	0
1075	Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice. Journal Francais D'Ophtalmologie, 2020, 43, 989-995.	0.4	0
1076	Emerging Role of CXCR4 in Fibrosis. RSC Drug Discovery Series, 2020, , 211-234.	0.3	0
1077	Comparison of two different treatment regimensâ€™ efficacy in neovascular age-related macular degeneration in Turkish populationâ€"based on real life data-Bosphorus RWE Study Group. International Journal of Ophthalmology, 2020, 13, 104-111.	1.1	4

#	Article	IF	Citations
1080	Angiography of Macular Diseases. , 2009, , 61-103.		0
1081	Novel Therapeutic Strategies For Posterior Segment Neovascularization. , 2008, , 445-526.		0
1082	Anti-VEGF Treatment for Age-Related Macular Degeneration. , 2007, , 53-66.		0
1083	Macular Disorders. , 2008, , 113-139.		0
1085	A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit. Molecular Vision, 2008, 14, 1358-72.	1.1	20
1086	Angioid streaks, clinical course, complications, and current therapeutic management. Therapeutics and Clinical Risk Management, 2009, 5, 81-9.	2.0	80
1087	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 159-66.	1.8	1
1088	Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clinical Ophthalmology, 2008, 2, 709-16.	1.8	27
1089	Intravitreal bevacizumab: an analysis of the evidence. Clinical Ophthalmology, 2007, 1, 273-84.	1.8	8
1090	Surgical removal of subfoveal choroidal neovascular membranes in older patients without age-related macular degeneration. Clinical Ophthalmology, 2007, 1, 157-65.	1.8	3
1091	Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Clinical Ophthalmology, 2007, 1, 167-75.	1.8	14
1092	Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin. Molecular Vision, 2009, 15, 1897-905.	1.1	10
1094	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evidence, 2008, 2, 273-94.	4.7	8
1095	KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization. Molecular Vision, 2011, 17, 797-803.	1.1	7
1096	Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration. International Journal of Ophthalmology, 2012, 5, 377-83.	1.1	1
1097	Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. Journal of Ophthalmic and Vision Research, 2009, 4, 105-14.	1.0	12
1098	Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review. Journal of Ophthalmic and Vision Research, 2012, 7, 235-9.	1.0	14
1099	Intravitreal Bevacizumab for posterior capsule neovascularization. International Journal of Health Sciences, 2011, 5, 30-1.	0.4	0

#	Article	IF	Citations
1100	Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2008, 3, 95-101.	1.0	6
1101	Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2008, 3, 102-7.	1.0	5
1102	The PEG-PCL-PEG Hydrogel as an Implanted Ophthalmic Delivery System after Glaucoma Filtration Surgery; a Pilot Study. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2014, 3, 3-8.	0.2	25
1103	The remote effects of intravitreal anti-VEGF therapy. Journal of Medicine and Life, 2016, 9, 392-398.	1.3	0
1105	Oleanolic Acids Inhibit Vascular Endothelial Growth Factor Receptor 2 Signaling in Endothelial Cells: Implication for Anti-Angiogenic Therapy. Molecules and Cells, 2018, 41, 771-780.	2.6	7
1106	A Novel Approach for Development of Intraocular Biodegradable Ranibizumab Implant: A Solution for Stability of Protein Activity. Advanced Pharmaceutical Bulletin, 2020, 11, 632-642.	1.4	2
1107	Discovery and Development of the Quininib Series of Ocular Drugs. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 33-42.	1.4	0
1108	Comparison of Machine Learning Methods Using Spectralis OCT for Diagnosis and Disability Progression Prognosis in Multiple Sclerosis. Annals of Biomedical Engineering, 2022, 50, 507-528.	2.5	26
1109	Ageâ€related Macular Degeneration (AMD). , 2008, , 50-50.		55
1114	Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin. Cancer Diagnosis & Prognosis, 2022, 2, 330-335.	0.7	0
1115	Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. International Ophthalmology Clinics, 2022, 62, 35-47.	0.7	1
1116	Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation. International Journal of Molecular Sciences, 2022, 23, 6455.	4.1	2
1117	Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting. International Ophthalmology, 0, , .	1.4	1
1119	Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration. Nature Communications, 2022, 13, .	12.8	28
1122	Research Trends and Hotspots of Retinal Optical Coherence Tomography: A 31-Year Bibliometric Analysis. Journal of Clinical Medicine, 2022, 11, 5604.	2.4	0
1123	Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy. Drug Design, Development and Therapy, 0, Volume 16, 3395-3400.	4.3	15
1124	Evaluation of effect of nilotinib in an experimental corneal neovascularization model. Anatolian Current Medical Journal:, 2022, 4, 431-437.	0.1	0
1125	A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration. Cells, 2022, 11, 3453.	4.1	16

#	Article	IF	Citations
1129	Progress on the application of growth factor-related drugs in ophthalmology. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 626-633.	0.3	0
1130	Ganglion cell complex changes in wet AMD patients treated with anti-VEGF intravitreal injections according to a treat-and-extend protocol. Canadian Journal of Ophthalmology, 2022, , .	0.7	0
1131	Decrease Retinal Thickness in Patients with Chronic Migraine Evaluated by Optical Coherence Tomography. Diagnostics, 2023, 13, 5.	2.6	0
1132	Promising Role of Silk-Based Biomaterials for Ocular-Based Drug Delivery and Tissue Engineering. Polymers, 2022, 14, 5475.	4.5	3
1133	Optical coherence tomography angiography patterns of type 1 macular neovascularization in age-related macular degeneration patients. European Journal of Ophthalmology, 2023, 33, 1697-1705.	1.3	1
1134	Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. Journal of Translational Medicine, 2023, 21, .	4.4	10
1135	Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023. International Journal of Retina and Vitreous, 2023, 9, .	1.9	0
1136	An Insight into the Development of Potential Antidiabetic Agents along with their Therapeutic Targets. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2024, 24, 50-85.	1.2	0
1137	Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns. Frontiers in Medicine, 0, 10, .	2.6	1
1138	Vascular Endothelial Growth Factor Receptor 1 Targeting Fusion Polypeptides with Stimuli-Responsiveness for Anti-angiogenesis. ACS Applied Materials & Interfaces, 0, , .	8.0	1
1139	Repurposing medications for treatment of age-related macular degeneration: Insights from novel approaches to data mining. Experimental Biology and Medicine, 2023, 248, 798-810.	2.4	1
1140	Prevalence of Geographic Atrophy in Advanced Age-Related Macular Degeneration (AMD) in Daily Practice. Journal of Clinical Medicine, 2023, 12, 4862.	2.4	3
1141	Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina. Acta Biomaterialia, 2023, 171, 273-288.	8.3	1
1142	Optical Coherence Tomography and Eye Care. New England Journal of Medicine, 2023, 389, 1526-1529.	27.0	0
1143	Correlation of the OCT Double-Layer Sign with Type 1 Non-Exudative Neovascularization on OCT-A in Age-Related Macular Degeneration. Medicina (Lithuania), 2023, 59, 1829.	2.0	0
1144	Response of Pigment Epithelial Detachment to Three-Loading-Dose of Intravitreal Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration. Cukurova Anestezi Ve Cerrahi Bilimler Dergisi, 2023, 6, 421-425.	0.0	0
1145	Recent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review. Biomedicines, 2023, 11, 3221.	3.2	0
1146	Update on treatments of diabetic macular edema. Chinese Medical Journal, 2009, 122, 2784-2790.	2.3	1

#	Article	IF	Citations
1147	Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges. Chinese Medical Journal, 2014, 127, 1550-1557.	2.3	2
1148	Age-associated macular degeneration: Epidemiologic features, complications, and potential therapeutic approaches. , 2024, , 381-429.		0